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ABSTRACT 
It is well known that exposure to toxicants in the environment is associated with a wide range 
of health effects. The airway epithelium which forms the first line of defense, plays critical 
roles in the defence against inhaled particles, pathogens and toxic agents. Therefore, good and 
valid human airway models need to be developed to study pathophysiological mechanisms of 
pulmonary toxicity mediated by xenobiotics. In this thesis, unique systems which combine 
different human airway cell models (ex vivo and in vitro) and different exposure methods were 
developed. After exposure, inflammatory and oxidative stress responses, interaction between 
different cell types, as well as the roles of Toll-like receptors (TLR) were addressed.  
In Paper I, we found that TLR ligands increased the release of pro-inflammatory cytokines and 
chemokines in alveolar macrophage (AMQ) from both healthy non-smokers and smokers with 
and without chronic obstructive pulmonary disease (COPD), and this induction was attenuated 
by co-stimulation with glucocorticosteroids. Glucocorticosteroids alone or combined with TLR 
ligands upregulated the TLR2 expression in AMQ from smokers with and without COPD. 
Hence glucocorticosteroids both exert an anti-inflammatory effect by inhibiting the 
inflammatory response and improvement of the host defense response by increasing the TLR2 
expression. This may be a contributing mechanism for the positive effect of 
glucocorticosteroids in the treatment of acute exacerbation caused by microorganisms in 
COPD. 
In Paper II-III, we succeeded in establishing human bronchial epithelial models (primary 
bronchial epithelial cell cultured at air-liquid interface (PBEC-ALI) with/without fibroblasts). 
In Paper IV, we built multi-cellular human bronchial models (PBEC-ALI co-cultured with 
macrophages (MQ); PBEC-ALI/MQ). After airlifting, the bronchial epithelial cells 
differentiated into ciliated cells, basal cells, mucus producing cells, and Club (Clara) cells 
which all are cell types present bronchial epithelium in vivo. Interleukin 13 (IL-13) induces 
mucus producing cell metaplasia and hyperplasia and was used to build up chronic bronchitis-
like models including an increased number of mucus-producing cells. By combining these 
models with a controlled aerosol exposure system (XposeALI), we developed an in vitro testing 
strategy to mimic in vivo conditions, a strategy which substantially reduces the need for animal 
models.   
In Paper II and III, we demonstrated that the induced inflammatory and oxidative stress 
responses and altered tissue injury/repair might be responsible for palladium/carbon 
nanoparticle mediated pulmonary toxicity. In addition, by comparison of inflammatory and 
oxidative stress response between normal and chronic bronchitis-like models, we found the 
latter to be more sensitive to particles exposure than the normal models. These results indicated 
that a pre-existing condition like chronic bronchitis, might lead to an increased risk of 
nanoparticle mediated health effect indicating an enhanced susceptibility to air pollution 
exposure in individuals with chronic lung disease compared with healthy subjects. 
In Paper IV, we showed that diesel exhaust particles, in PBEC-ALI models, induced 
inflammatory and oxidative stress responses that were attenuated in the presence of MQ. In 
PBEC-ALI/MQ, diesel exhaust particle exposure increased the mRNA expression of M2-MQ 
markers which was not observed in mono-cultures (PBEC-ALI or MQ). These findings 
indicate that the cross-talk between epithelial cells and MQ, together with particle exposure 
can drive MQ polarization towards M2-subtype. Therefore, interactions between PBEC and 
MQ play an important role in resolution of the inflammatory response upon particle exposure. 
Taken together, this thesis indicates the role of TLR mediated inflammatory response and 
oxidative signaling pathway as well as cell-cell interactions after exposure to various toxic 
components on different lung cell models related to COPD and chronic bronchitis. 
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1 INTRODUCTION 
With the rapid development of industrialization, death from environmental degradation has 
become a huge threat to the public health. Pollution is one of the leading environmental hazards 
that affects our daily lives. According to a report from World Health Organization (WHO), in 
2012, around 7 million people died and one in eight of the total global deaths is directly linked 
to air pollution exposure. This report in 2014 confirmed that air pollution represents the world´s 
largest signal environmental health risk[1]. Air pollution involves inhalation exposure to 
particulate matter (PM), gases and fumes including metal fume and may contribute to the 
development of cardiopulmonary diseases and lung cancer[1]. However, the mechanism of 
xenobiotics induced potential lung toxicity remains relatively unknown primarily due to the 
lack of efficient test systems which can mimic human exposure scenarios to aerosolized air 
pollutants. 
Therefore, in this thesis, we developed different cell models including single and multiple cell 
types and combined with submerge/aerosol exposure. These models were used to identify the 
cross-talk between cells as well as the Toll-like receptor mediated inflammatory and oxidative 
signaling pathway after exposure to various particles existing in air pollution.  
1.1 THE RESPIRATORY SYSTEM  
The human respiratory system is a biological system responsible for exchanging carbon 
dioxide and oxygen. For an adult at rest, the normal respiration rate is 12-20 breaths/min and 
normal minute volume is approximately 7.5 L/min. Inhaling air enters into the respiratory 
system through the nose or mouth and passes through the trachea, bronchi and bronchioles 
and finally reaches the alveoli. The respiratory system can be divided into upper and lower 
airways. The upper airway consists of the nasal cavities, pharynx and larynx. The lower 
airway which divides into two main bronchi after which there is dichotomous divisions of 
the airways down to terminal and respiratory bronchioles, alveolar ducts and alveoli. The 
airways are lined with ciliated epithelial cells which functioned as a mechanical barrier. The 
synchronized cilia beating transports mucus produced by mucus producing cells located in 
the airway epithelium or submucosal glands towards pharynx. This mucociliary clearance 
clears the airways from inhaled particles which are trapped in the mucus and prevent 
accumulation of mucus in the lung.  
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The alveolar epithelial cells consist of flat alveolar type I (ATI) cells (90% of the alveolar 
surface) and cuboidal alveolar type II (ATII) cells (10% of the alveolar surface). Both of 
them are not ciliated and have direct contact with the capillary endothelium where the gas 
exchange occurs. Figure1 indicated the anatomy of respiratory system (Figure1A) and 
cellular transition of airway and alveolar epithelial layer (Figure1B).  
 
Cigarette smoke or exposure to pollutants impair the mucociliary clearance and increase 
mucus secretion which induce the risk of airway infections[2, 3]. The abnormalities in mucus 
production and clearance contribute to airway obstruction, lung function decline and lead to 
respiratory disease. Chronic respiratory diseases are diseases affecting airways which 
hundreds of millions of people suffered from. The most common chronic respiratory diseases 
are chronic obstructive pulmonary disease (COPD), chronic bronchitis and asthma. 
1.1.1 Chronic Obstructive Pulmonary Disease (COPD) 
Chronic Obstructive Pulmonary Disease (COPD) is a multi-component disease with 
inflammation in the large/small airways (bronchitis/ bronchiolitis) and lung parenchyma 
destruction which lead to the abnormal airway space enlargement (emphysema)[4]. It affects 
up to 10% of the population world-wide and it is estimated to be the third leading cause of 
death in 2020[5, 6]. During the last decade moderate and severe COPD is also recognized as a 
systemic disease with signs of systemic inflammation[7] and a massive co-variation with other 
conditions such as cardiovascular disease, asthma, osteoporosis, skeletal muscle dysfunction, 
cognitive dysfunction, and diabetes[8, 9]. 
In this thesis, the classification of COPD refers to Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) criteria[10] (table 1). The classification of severity is based on lung 
function as assessed by spirometry.  
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Tobacco smoking is the most important risk factor of COPD. Although not all cigarette 
smokers will develop the disease, approximately 50% of the smokers who reach the age of 75 
years develop COPD[11]. Also exposure to gases, dust or fumes in the workplace increase the 
risk of COPD. In general population, approximately 15% of all cases of COPD are due to 
occupational exposure including coal or metal mining, construction and farming biomass[12]. 
Long-term exposure to air pollution contributes to the development of COPD[13], and short-
term exposure to air pollutions may cause acute exacerbations in subjects who suffer from the 
disease[14]. Alpha-1 antitrypsin (AAT) deficiency is strongly associated with COPD, 
especially in smokers. Up to 5% of people with COPD have been estimated to have AAT 
deficiency[15].  
The COPD is associated with irreversible damage of the lungs. Acute exacerbations of COPD 
drive impaired health related quality of life, increase symptoms, increase the risk of infections, 
increase lung function decline over time, increase the risk of hospitalization and increase 
mortality in patients. The goals of COPD treatment include relief of symptoms, limitation of 
disease progression, prevention of exacerbations and reduction of morality[16]. Smoking 
cessation is the most effective treatment for COPD, and it is the only proven way of influencing 
rate of decline in lung function with time[17]. Physiotherapy is an important component in the 
treatment of COPD as is pharmacological treatments including long acting bronchodilators (β2-
agonists (LABA) / anticholinergic agents) and glucocorticosteroids.  
Inhaled corticosteroids (ICS), in particular when combined with long-acting beta-2-agonists 
have been shown to improve health status and reduced the exacerbation rates[18]. 
Glucocorticosteroids like budesonide (Bud) is a class of corticosteroids and widely used for the 
treatment of COPD. As an  anti-inflammatory drug, it can bind to intracellular glucocorticoid 
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receptors (GRs) and co-operate with transcription factors to downregulate pro-inflammatory 
genes and/or upregulate anti-inflammatory genes transcriptions[19]. The combination of 
glucocorticosteroids and LABA have been proved to be of greater beneficial effect than each 
of them alone[18]. This synergistic effect is due to that on one hand glucocorticosteroids can 
modulate the function of β2-adrenoceptors thereby preventing the tolerance induced by β2-
agonists[20], on the other hand LABA seems to facilitate the GRs translocation into the 
nucleus[21]. 
Anticholinergic agents are the drugs of choice to treat COPD. Recent studies[22] have 
demonstrated that beneficial clinical effects of anticholinergics in COPD are mediated, not only 
by blocking parasympathetic nerve impulses in the bronchial smooth muscle, but also by 
interacting with inflammatory cells. 
1.1.2 Chronic bronchitis 
Chronic bronchitis is a disease associated with structural changes of large and medium-size 
airways which are mainly caused by tobacco smoking. Some other risk factors such as air 
pollution and occupational airborne exposures have been also identified[23]. The definition of 
chronic bronchitis is: daily chronic coughing and sputum production for at least 3 months a 
year for 2 years in a row. It is characterized by metaplasia, hypoplasia and a much more 
peripheral distribution of goblet cells compare with healthy non-smokers, as well as increasing 
submucosal gland size which leads to increased mucus production[24]. This in turn decrease 
mucociliary clearance and destroyed cilia, broken epithelial barrier and thickening of the 
bronchial wall[25]. Chronic bronchitis is a commonly neglected co-morbidity of COPD, one 
that further increases morbidity and mortality in an independent manner[26]. 
1.2  CELLS INVOLVED IN HOST DEFENCE 
In human body, the innate and adaptive immune system work as the defense against a variety 
of pathogens and infections. The respiratory tract host defense is provided by immune effector 
cells (alveolar macrophages, neutrophils and dendritic cells) and structural cells (epithelial cells 
and fibroblasts). They cooperatively participate in the orchestration of immune responses as 
they all express pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), 
nucleotide binding and oligomerization domain-like receptors (NOD or NLRs), retinoic acid-
inducible gene 1-like receptors (RLRs) on their cell surface. The PRRs recognize pathogen 
associated molecular patterns (PAMPs) on bacterial and viral pathogens[27, 28] or danger-
associated molecular patterns (DAMPs) from damage tissue. 
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1.2.1 Macrophage  
Macrophages (MQ) is a population of phagocytic cells which are derived from blood 
monocytes, and play important roles in non-specific defense mechanisms involved in the 
defense against external insults[29]. They are able to modulate the adaptive immune responses 
of the host by secreting and responding to a variety of effector molecules[30]. Two major 
polarization states of macrophages have been described: the classically active type1 (M1) and 
alternatively activated type 2 (M2). M1 macrophages are characterized by high production of 
pro-inflammatory cytokines, reactive nitrogen and oxygen intermediates (RNIs and ROIs) as 
well as by a strong ability to mediate resistance to pathogens and microbicide properties[31]. 
Lipopolysaccharides (LPS), IFN-γ and TNF-α stimulate the classical pathway of M1 
activation[32]. In contrast, M2 macrophage are characterized by secreting anti-inflammatory 
cytokines with limited production of pro-inflammatory cytokines[33] and they are considered 
to have wound-healing properties with induction of scavenger, mannose receptor 1 or 2 (MRC-
1/MCR-2) and adipokine resistin-like molecule alpha (Retnla) expressions[34]. Interleukin 
(IL)-4 and IL-13 or immune-regulatory signals like IL-10 can drive the polarization of 
macrophage skew towards the M2 phenotype[32]. Phenotypic alteration of MQ is considered 
to play a pivotal role in the pathogenesis of chronic airway diseases and has potential 
implications for the treatment of chronic respiratory diseases like COPD and asthma[35]. 
1.2.2  Bronchial epithelial cells  
Airway epithelium plays a protective role against inhaled xenobiotics. It is pseudostratified in 
the large airways and becomes columnar and cuboidal in the small airways[36]. In vivo, human 
bronchial epithelium consists of ciliated cells (50-70 %), basal cells (30 %), mucus producing 
cells (25 %) and Club (Clara) cells (11 %)[37].  
Ciliated cells are usually equipped with up to 300 cilia per cell and contain numbers of energy-
producing mitochondria close to their apical surface[38]. Matured cilia shows the ultra-
structure of axoneme with two central singlet and nine outer doublet microtubules which can 
be stained with anti-acetylated alpha tubulin antibody[39]. With the cilia beating, the 
mucociliary clearance is performed by moving the mucus continuously up to pharynx, thus 
inhaled agents which are embedded in the mucus are gradually cleared away.  
Mucous (goblet) producing cell is membrane-bound and include acidic mucin granules, which 
can secret mucus that increase the  physical barriers to trap inhaled agents[40]. Mucin 5AC 
(MUC5AC) is one of the major gel-forming secreted mucins expressed by mucous producing 
cells[41]. Under normal conditions mucus protects the airway epithelium and is an important 
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part of the mucociliary clearance defense. However, abnormalities in mucus secretion or 
clearance can engender respiratory disease. For instance, chronic bronchitis which is usually 
characterized by chronic hypersecretion of airway mucus and further lead to airway 
obstruction, lung function declination and mortality[42, 43]. Both IL-4 and IL-13 can induce 
metaplasia or hyperplasia of mucous producing cells and can also increase MUC5AC 
secretion/expression[44], which are the characteristic features of chronic bronchitis.  
Club (Clara) cells usually have stem cell properties and regard as progenitor cells for ciliated 
cells[45]. Club cells can produce club cell protein also known as: uteroglobin, club cell protein 
16 (CC16) or club cell protein 10 (CC10)[45]. Club cell protein has an anti-inflammatory effect 
and its expression in bronchial epithelium of COPD patients and smokers with chronic 
bronchitis has been shown to be significantly decreased compared with healthy controls or 
smokers without chronic bronchitis, respectively[46, 47].   
Basal cells are located beneath other epithelial cells and firmly attached to the basement 
membrane. They are also considered as stem cells and can give rise to stroma or columnar 
epithelial cell[48]. 
Bronchial epithelial cells at air-liquid interface (ALI) 
Traditionally, in vitro studies have been performed by culturing the cells submerged where 
medium and target agents were added on top of the cells to cover the cells. For primary contact 
organs such as the lung, exposure to externa agents occurs at ALI implicating that the submerge 
condition does not resemble the in vivo situation associated with exposure in human respiratory. 
Moreover, the bronchial epithelial cell cultures under submerged conditions develop a 
squamous phenotype, while under ALI conditions the epithelial cells differentiate into 
pseudostratified epithelial layer which contains ciliated cells mucus producing cells, club cells 
and basal cells. Thus, ALI culture mimic is similar to the in vivo situation. Now more and more 
ALI cultures are commercially available at the market (MucilAirTM-HF and EpiAirwayTM) and 
different ALI exposure systems have been developed to gain an insight of inhalation toxicology 
research[49-51]. 
1.2.3 Crosstalk between macrophage and bronchial epithelial cells 
The cooperation between macrophages and epithelial cells are important as they both work 
within the first line of defense against inhaled toxic agents on both airways and alveolar levels. 
Previous studies have shown that bronchial epithelial cells[52] recognize conserved PAMPs 
through apical TLRs including TLR2 and TLR4, and subsequently induce the secretion of pro-
inflammatory cytokines and chemokines, which in turn stimulate recruitment and activations 
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of phagocytes like macrophage to the site of infections[53]. Macrophages in itself is also 
equipped with TLRs that recognize a wide spectrum of inhaled particles or pathogens and 
consequently contribute to the cytokines production. The synthetization of cytokines from both 
cell types may induce inflammation and contribute to the development of airway disease like 
COPD and asthma[54]. Interestingly, it has also been reported that bronchial epithelial cells 
can regulate the TLRs sensitivity to avoid the risk of continuous inflammation and limit the 
release of pro-inflammatory cytokines by innate immune cells like macrophages[55].  
1.3 TOLL-LIKE RECEPTORS  
Toll-like receptors (TLR) are a class of PRRs enabling cells to recognize PAMPs from 
microorganisms or DAMPs from tissue injury. Structurally, TLRs are type I transmembrane 
glycoprotein on the basis of: an amino (N)- terminal extracellular domain consist by horseshoe-
like leucine rich repeats (LRRs); a single transmembrane region; a carboxyl (C)-terminal 
intracellular Toll/interleukin-1 receptor (TIR) domain contains three highly homologous 
regions (box 1, 2 and 3)[56]. To date, 10 human and 12 mouse TLRs have been identified. In 
human beings, TLRs can be subdivided into two groups depending on the site of expression. 
One type is expressed at the cell surface and detect PAMPs in microbial membranes and 
flagellin (TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10). The other type is expressed within 
the intracellular compartments and are activated by PAMPs in nucleic acids derived from 
bacterial and viral pathogens (TLR3, TLR7, TLR9 and TLR10)[57].   
1.3.1 TLRs signaling  
TLRs signaling can be classified as either myeloid differentiation primary-response protein 88 
(MyD88)- or TIR-domain-containing adapter-inducing interferon-β (TRIF)- dependent 
pathways[58].   
MyD88 dependent pathway 
Upon activation, MyD88 can directly bind to TIR domains of TLR or with the help of MyD88 
adaptor-like (MAL)/ TIR domain-containing adaptor protein (TIRAP). The association of 
MyD88 and interleukin-1 receptor-associated kinase (IRAK) 4 induces phosphorylation of 
IRAK1. Activation of IRAKs recruits TNF receptor associated factor (TRAF) 6 to the receptor. 
Then IRAK1/TRAF6 dissociates from receptor and form a complex with transforming growth 
factor beta-activated kinase1 (TAK1), TGF-beta activated kinase (TAB) 1 and TAB2. Then 
TAK1 become phosphorylated and this process activates IκB kinase (IKK) complex or 
mitogen-activated protein kinas (MAPK). The activation of both kinases allowing nuclear 
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factor kappa-light-chain-enhancer of activated B cells (NF-κB) or activator protein 1 (AP-1) to 
translocate into nucleus and induce the expression of target genes.  
TRIF-dependent pathway 
Upon activation, TRIF directly or with the help of TRIF-related adaptor molecular (TRAM) 
associated to TRAF6 or TRAF3. The engagement of TRAF3 can trigger TANK binding kinase 
1 (TBK1) mediated interferon regulatory factor 3 (IRF3) activation and increased type I 
interferon (IFN)s production.  
Negative regulation of TLR signaling 
Excessive activation of TLR signaling may disrupt the immune homeostasis and initiate 
inflammatory and autoimmune diseases. Therefore, a negative control of TLR signaling seems 
very important to keep the balance of the immune system. There are several mechanisms 
involved in this negative regulation[59]. The major mechanism is to reduce the function and 
expression of TLR. Another mechanism is including intracellular negative regulators like 
IRAK-M, MyD88 short, SOCS1 etc.[60].  
1.3.2 TLR2 and TLR4 
Because of their ability to recognize a variety of pathogenic ligands (both endogenous and 
exogenous), TLR in general but especially TLR2 and TLR4 have received great attention since 
they were discovered.  
TLR2 is localized on the cell surface, and form heterodimers with TLR1 or TLR6 to identify a 
wide range of ligands including peptidoglycan (PGN) and lipoteichoic acid (LTA) from Gram-
positive bacteria, bacterial lipoproteins and lipopeptides, envelope proteins from virus etc.[61].  
TLR4 is the first TLR to be characterized and well-studied[62]. Several ligands for 
instance  lipopolysaccharide (LPS) from Gram-negative bacteria and fusion and envelope 
proteins from virus stimulate TLR4[63]. LPS is one of the immuno-stimulatory membrane 
components that elicits a strong systemic inflammation. LPS is directly captured by a soluble 
shuttle protein, LPS binding protein (LBP), and by that facilitates LPS binding to cluster of 
differentiation 14(CD14) on the cell surface[64]. CD14 is a glycosylphosphatidylinositol-
anchored protein on the surface of monocyte/macrophage which delivers the LPS-LBP 
complex to TLR4/MD-2 receptor and realize LPS recognition[65]. As MD-2 is in a soluble 
form and not covalently bound to TLR4, it can also independently be associated with LPS 
without TLR4 present[66]. In addition to binding of exogenous ligands, TLR2 and TLR4 also 
interact with endogenous ligands formed under stress or tissue injury. Heat shock proteins 
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(HSP) like HSP60, HSP70, HSP90, GP96 and HSP22 are endogenous ligands for TLR2 and 
TLR4[67, 68]. The high-mobility group box 1 (HMGB1) and small molecular weight 
fragments of hyaluronic acid (HA) from damaged cells are recognized by TLR2 and TLR4 and 
triggers inflammation[69, 70]. Upon stimulation, TLR2 signaling go through the MyD88-
dependent pathway and TLR4 activate both MyD88- dependent and TRIF- dependent 
pathways (Figure 2 left).  
 
In previous studies it has been found that TLR2 mRNA expression was lower in sputum 
neutrophils and alveolar macrophages from smokers with COPD than in healthy controls[71, 
72]. Further it has been shown that TLR4 mRNA and protein expression were down-regulated 
upon cigarette smoke extracts exposure in an airway epithelial cell line[73]. All of these 
findings confirmed the important roles of TLR2 and TLR4 in host defense mechanisms.  
1.4 PARTICULATE MATTER 
Particulate matter (PM) is one of the major health risk components in air pollutions. It is a 
mixture of solid and liquid particles suspended in air which with a great variation of particle 
size, number, composition, and origin. According to aerodynamic diameter, PM is generally 
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classified into 3 subtypes: PM10 (coarse particles, median aerodynamic diameter (MAD) 
≤10µm), PM2.5 (fine particles, MAD ≤2.5µm) and UFP (ultrafine particles, MAD≤0.1µm). 
Long-term exposure to PM increases morbidity and mortality of many diseases such as 
cardiovascular diseases, cancer and pulmonary diseases[74, 75]. For instance, people who are 
living near a major road with chronic exposure to PM10 showed a high risk of development of 
COPD and lung function loss[76].  
1.4.1 Nanoparticles  
The PM with at least one geometric dimension smaller than 0.1 µm are known as 
nanoparticles[77]. Although humans have been exposed to nanoparticles for a long time, 
nowadays inhalational exposure to nanoparticles is of great concern not only from the 
occupational point of view but also for the environmental daily exposure to airborne 
nanoparticles.  
Palladium nanoparticles (Pd-NP)  
The Pd-NP have a size around 10 nm. The Pd-NP possess high chemical activity and are 
broadly used as catalysts in automotive and in chemical or processing industries. Additional 
use in electrical equipment, jewelry and dental appliances also contribute to environmental Pd-
NP load[78]. Due to the small size, they result in a relative stable aerosol that could reach down 
to the alveoli in the lungs, but deposition may also occur higher up in the airway tree 
particularly at the bifurcations[79]. 
Carbon nanoparticles (CNP)  
The CNP which have the size less than 100 nm. They are generated by incomplete fuel and 
diesel combustion, as well as in connection to indoor cooking or open air fire[80-82]. They are 
also involved in manufacturing of black ink, in paint, plastic, and reinforcing agents for rubber 
goods[83]. The concern of the risk of CNP arises because of their large effective surface area, 
great deposition rate and high toxicity[84, 85]. Similar to Pd-NP, CNP is deposited throughout 
the whole respiratory system and may cause unwanted effects both locally and systemically by 
crossing the alveolar-capillary barrier and enter into blood stream[86].  
1.4.2 Diesel exhaust particles  
Diesel exhaust particles (DEP) are a complex mixture of particles (< 1.0 μm in diameter) and 
form a source of PM in ambient air and occupational settings. All DEP fresh from the engine 
are below 1 µm, with very few particles above 500 nm in size. The outer shell of DEP consists 
of metals (copper/zinc) as well as polycyclic aromatic hydrocarbons (PAHs) (anthracene or 
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benzo[a]pyrene (B[a]P))[87]. The DEP are products of incomplete combustion of diesel fuel 
in engines. Although the new diesel engines have been improved to produce lower levels of 
PM, increased ultrafine particles and nanoparticles are still produced[88]. Due to the high 
efficiency robustness and low running costs, diesel engines are widely used in the mass 
transportation including buses, heavy duty vehicles and off-road equipment, which elevated 
the concern about DEP´s health effects[89]. The DEP have the potential to penetrate deep down 
in the respiratory tract[90, 91]. Exposure to DEP in human results in marked pulmonary and 
systemic inflammatory responses involving different cell types[92]. Also chronic exposures is  
associated with long-term adverse effects, like cough, respiratory infections and lung function 
decline[93].  
1.5 NOVEL CELL EXPOSURE SYSTEM – PRECISEINHALE: XPOSEALI 
During recent decades, increasing efforts have been put on the development of systems being 
able to deposit aerosols on cell surfaces of cells cultured at ALI[94]. It was a breakthrough 
in in vitro research field, when techniques for exposure to aerosols including particles was 
possible by deposition on a cellular layer without suspending particles, in a solution as during 
submerged culturing. Although, some commercial cell exposure systems like ALICE, 
Vitrocell and Cultex® RFS[95-97] are available, the development of new technology is still 
under fast progress.  
PreciseInhale™ exposure platform (Figure 3) which was established by Inhalation science 
Sweden AB is an advanced exposure system with different exposure modules. It can mimic 
the exposure situation in vivo which makes it possible to identify how inhaled particle act 
and affect the lung. In general, aerosol exposure of cell models requires a two-stage set-up: 
aerosol generator and cell exposure module. In PreciseInhale exposure platform, 
PreciseInhale aerosol generator can drive aerosolisation powerfully by high pressure and 
generates well dispersed particles through de-agglomeration[98]. The precise dosing system 
by the use of the Casella impactor enables an automatically dose control of the generator at 
each experiment. Then XposeALI® which is a newly developed cell exposure module is 
coupled to PreciseInhale aerosol generator. XposeALI consists of three test cups which are 
connected with three mass flow regulators controlled by a computer. A reverse flow pattern 
is used to regulate excess aerosol from the periphery to one central outlet, and subsequently 
collected in a filter at the end of the central outlet.  
In addition to precise dosing, there are three more advantages of PreciseInhale exposure 
platform. Firstly, the amount of required particles is minimal implicating that only small 
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portions of the produced particles are needed to produce a respirable aerosol. Usually, not 
more than 50 mg particles can be enough for a whole study. Secondly, the deposition of 
particles is evenly distributed over the cell surfaces. The compressed air can disperse particles 
to aviod its agglomeration. Even nanopartilces which contain high cohesive energies can be 
well dispersed by the compressed air generated by the platform. Because of the electrostatic 
influence, some particles tend to stick to the insert wall. But in PreciseInhale exposure 
platform, the exposure hoods restrict to the exposure area available for particles of the inserts. 
Then the particles can be trapped inside of the exposure hoods, and directly exposed to the 
cell surface which avoid unwanted contamination. Thirdly, it is possible to keep the exposure 
time short. The high pressure of the compressed air can achieve sufficient aerosol deposition 
within short time. This can minimize the time for models being out of the incubator and 
which reduces the risk of infections and/or decreased viability. In this thesis, for all the 
studies, the maximal exposure time was around 7 minutes but usually a shorter exposure time 
was used depending of the dose.  
 
1.6 INFLAMMATORY MEDIATORS  
Inflammation is a complex of biological responses of tissues/organs and occurs upon exposure 
to harmful stimuli (damaged cells, microbial pathogens, irritants and toxic components), and 
controlled by different kind of mediators[99]. The classical manifestations of inflammation are 
pain, heat, redness, swelling and finally loss of function[100]. Cytokines with a pleiotropic 
activity are the regulators of host responses to inflammation. They are proteins which can be 
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produced by nearly all type of cells[101]. The grouping of cytokines is based on their original 
biological description (interleukins, tumor necrosis factors, interferons and chemokines) 
structural homology of their receptors (class I and II cytokines) or their roles in inflammation 
(pro- and anti- inflammatory cytokines)[102]. Pro-inflammatory cytokines tend to promote 
inflammation and make diseases worse while anti-inflammatory cytokines act to suppress the 
inflammation[99]. Different cytokines are signalling in different ways, they can act on the same 
cell that produced the cytokines (autocrine mode), affect a neighboring cell near (paracrine 
mode) or far from the cytokine secreting cells (endocrine mode)[102].  
One of the characteristics features of COPD is inflammation in the respiratory tract and lung 
tissue and acute exacerbations of COPD is associated with enhanced inflammation. A variety 
of cell-types like structural lung cells (epithelial cells, fibroblasts) and immune cells 
(macrophages, neutrophils, lymphocytes ) are contributing to the inflammation in COPD[103]. 
Also different inflammatory biomarkers varies both locally and systemically in COPD 
patients[7]. More than 50 cytokines have been shown to be associated with COPD, although 
not all of their roles have been clearly identified[104]. Some of them are of particular 
importance for this thesis are listed below.  
Interleukin 6 (IL-6) is a cytokine with pleiotropic effects (exert acute phase/immune response 
and change hematopoiesis) which is secreted by T-cells, B-cells, macrophages and epithelial 
cells[105]. IL-6 exhibits both pro-and anti-inflammatory capacity depending on presence of 
other cytokines or the target cell types[106]. It can stimulate the acute phase proteins 
productions after exposure to different stimuli and favor the transition between acute and 
chronic inflammatory responses[107]. In COPD patients, especially during exacerbations, the 
levels of IL-6 have been found to be increased in induced sputum, BAL-fluid and serum[24].    
Tumor necrosis factor alpha (TNF-α) is a key cytokine involved in inflammatory response. It 
is produced predominantly by activated macrophages, although it can also be secreted by other 
cell types including immune cells (T and B lymphocytes, neutrophils, mast cells, natural killer 
(NK) cells etc.), structural cells (epithelial cells, smooth muscle cells, fibroblasts etc.) and 
neurons[108]. TNF-α can regulate production of other cytokines, activate the extracellular 
matrix (ECM) expression and stimulate growth[101]. There are two isoforms of TNFα, 
membrane tethered a 26-kDa cytokine (mTNF-α) or a 17-kDa cytosolic soluble form (sTNF-
α)[109]. TNF-receptor 1 (TNFR1, p55 receptor) and 2 (TNFR2, p75 receptor) interact with 
TNF-α[110]. TNFR1 is widely expressed in most cell types, and respond to both mTNF-α and 
sTNF-α, while TNFR2 is typically expressed with restricted levels in cells of the immune 
system, and only respond to mTNF-α[111]. Cell surface bound TNFR can be released to 
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cytoplasm by proteolytic cleavage as a response to inflammatory mediators[112]. The TNF-α 
regulated pathways are complex and still not fully understood. By binding to TNFR, TNF-α 
can active MAPK and NF-κB pathways, and induce death signaling[104]. This route has been 
implicated in the pathophysiology of many inflammatory diseases, like COPD and chronic 
bronchitis. The sputum concertation of TNF-α have been found to be high in COPD 
patients[113], especially during exacerbations[114]. In serum, the level of TNF-α has been 
found to be increased in patients with severe COPD with cachexia[115]. However, in mild or 
moderate COPD, levels of TNF-α in saliva and serum as well as BAL macrophage TNF-α 
mRNA expression were found to be slightly attenuated[7].   
Interleukin-8 (CXCL8/IL-8) is an abundant and well-studied chemokine. It is not stored 
intracellularly and it is produced by various cell types like macrophages, epithelial cells and 
endothelial cells etc.[116]. The main function of CXCL8 is to work as a potent chemoattractant 
to recruit neutrophils. Also, CXCL8 is responsible for activation and migration of other 
immune cells to inflammatory sites[117], for inducing cell phagocytosis[118], initiating 
respiratory burst[119] and promoting angiogenesis[120]. The effects of CXCL8 are triggered 
by binding to CXCR1 (low affinity receptor and displayed a relative selectivity for 
CXCL8) and CXCR2 (high affinity receptors and shared by many chemokines)[104]. As a 
neutrophilic chemotactic factor, it is not surprising that CXCL8 are important during the 
development of lung diseases like COPD. Compared with health controls the levels of CXCL8 
have been found to be significantly higher in induced sputum[7] and BAL fluid[121] in COPD 
patients with further increase during exacerbations[114]. A negative relationship between 
saliva levels of CXCL8 and lung function index was also found in COPD patients[7]. Airway 
epithelial cells and alveolar macrophages from COPD patients secreted more CXCL8 than cells 
from smokers without COPD[122, 123].   
Matrix metalloproteinases (MMPs) is a family of zinc-dependent proteinase. It is mainly 
produced by monocytes/macrophages, but neutrophils, eosinophils and some of the structural 
cells like epithelial cells are also known cell sources[124, 125]. MMPs play key roles in causing 
extensive alterations of lung extracellular matrix (ECM) as they are able to cleave structural 
proteins[126]. Matrix metalloproteinases-9 (MMP-9) is expressed at low levels in healthy lung 
but overexpressed in many lung diseases[126]. It is involved in lung epithelial wound repair by 
remodeling the provisional ECM and control the migration of repairing cells[127]. The activity 
of MMP-9 is usually regulated by tissue inhibitor of metalloproteinases-1 (TIMP-1), and the 
imbalance between MMP-9 and TIMP-1 might be  associated with lung tissue degradation 
leading to airflow obstruction[128]. Previous studies have shown that MMP-9 and MMP-
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9/TIMP-1 levels were elevated in induced sputum[128], BAL fluid[129] and serum[7, 130] in 
COPD patients compared to heathy controls. Interestingly, one of our studies identified a 
negative relationship between salivary MMP-9 and lung function index (FEV1)[7]. 
Interleukin-13 (IL-13) is a T helper type 2 (Th2) cells cytokine, which also can be synthesized 
by other cells like CD4 cells, mast cells, NK cells, basophils etc.[131]. Both in vitro (bronchial 
epithelial cells culture) and animal studies have demonstrated that, IL-13 induces mucus 
producing cell hyperplasia and stimulate the secretion of mucin via epidermal growth factor 
receptor (EGFR) activation[132, 133]. Mucus hypersecretion is a clinical hallmark of chronic 
bronchitis, and smokers with chronic bronchitis have more IL-13 expressing cells in bronchial 
mucosa than smokers without chronic bronchitis[134]. The IL-13 also decreases mRNA 
expression of cilia-related markers[135] and attenuates the epithelial cell capacity of 
maintaining its barrier function and/ or wounds repair[136]. 
1.7 OXIDATIVE STRESS  
Oxidative stress is a condition caused by an imbalance between oxidants and anti-oxidants 
leading to increasing levels of intracellular reactive oxygen species (ROS)[137]. ROS consists 
of superoxide anion (O2-), hydrogen peroxide (H2O2), and hydroxyl radicals (OH
-) and are 
generated from both endogenous (normal cellular metabolism) and exogenous (exposure to 
environmental factors like air pollutants, irradiation or cigarette smoke) sources. High levels of 
ROS lead to cell damage including disruption of cell protein function and alternate DNA 
expression[138]. Therefore, ROS plays fundamental roles in cell viability, proliferation and 
organ function, as well as contributing to the pathogenesis of many chronic inflammatory 
airway diseases, such as COPD and asthma[139]. 
The survival of cells against oxidants is dependent on the intracellular redox homeostasis, 
which is maintained by the balance of ROS generation and elimination (conducted by anti-
oxidant systems)[140]. After being activated by oxidative signals, transcription factor, NF-E2 
related factor 2 (Nrf2), will leave Nrf2-Keap1 complexes which translocate into the nucleus. 
By binding to the anti-oxidant response element (ARE) in the promoter region[141], it will 
increase the anti-oxidant gene transcription potential (Figure 2 right). The main functions of 
anti-oxidants are scavenge superoxide and free radicals, and subsequently detoxify free radicals 
[142]. The major class of anti-oxidant enzymes includes heme oxygenase-1 (HMOX-1), 
glutathione peroxidase (GPx), superoxide dismutase (SOD), catalases and glutathione S-
transferases (GSTs). Besides, ROS can regulate the activity of NF-κB and further moderate the 
inflammatory gene expression by various pathways. For instance, ROS can directly or 
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indirectly (by activate and inactivate the IKK complex) influence phosphorylation of 
IκBα[143]. Also, ROS can alternate the DNA binding properties of the NF-κB proteins 
themselves[144]. 
Heme oxygenase (HMOX) can catalyze the oxidative degradation of heme by interaction with 
molecular oxygen and cytochrome p450 reductase, resulting in the generation of carbon 
monoxide (CO), iron and biliverdin-Ixα[145]. Actually, HMOX also exerts anti-oxidative, 
anti-inflammatory and anti-proliferative properties via the products formed during these 
reactions. As examples the ability of CO to inhibit cell proliferation[146] and the sequestration 
of iron  by ferritin with accompanying  antioxidant[147] and anti-apoptotic[148] effects could 
be mentioned. Biliverdin-Ixα will eventually be reduced to bilirubin-Ixα by biliverdin 
reductase, and bilirubin-Ixα can function as antioxidant and anti-inflammatory mediator[149].  
Heme oxidant + O2 + NADPH: 
HMOX
→     CO + Fe2+ + biliverdin − Ixα 
Two HMOX isoforms are known in humans, an inducible isoform (HMOX-1) and a 
constitutive isoform (HMOX-2). During hyperoxia, HMOX-1 is a strongly and highly 
regulated enzyme, and induced by a variety of lung cells, like alveolar macrophages, epithelial 
cells and fibroblasts[150]. It has been reported, that HMOX-1 expression was associated with 
COPD pathogenesis[145]. Level of HMOX-1 was increased in the alveolar spaces of smokers 
with and without COPD compared to non-smokers[151]. In alveolar macrophage, HMOX-1 
expression was lower[152] while numbers of HMOX-1+ alveolar macrophage was higher[151] 
in smokers with COPD than non-smokers.  
GPx usual bind to the selenocysteine (Sec) and converts peroxides, hydroxyl radicals or lipid 
hydroperoxides into water and alcohol[153, 154]. This process often concomitants with the 
oxidation of reduced glutathione (GSH) into oxidized glutathione (GSSG)[155]. With the help 
of glutathione reductase, GSSG can be recycled to GSH, which can keep intracellular GSH in 
an appropriate level[156]. 
ROOH + 2GSH 
GPX
→   OH + GSSG + H2 O 
There are 8 GPx isoforms (GPx-1-8) in humans, with GPx-1 as the most abundant isozyme 
which localized in the cytoplasm and can be found in nearly all tissues[154]. In respiratory 
system, there is a high amount of GPx in alveolar epithelial lining fluid, also cells like primary 
bronchial epithelial cells or alveolar macrophages can synthesize and secrete GPx[157]. It has 
been proved that GPx activity is associated with lung function impairment in COPD, assessed 
as decreased FEV1[158]. According to recent studies[159, 160], GPx activity was significantly 
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reduced in smokers and COPD patients, and the reduction was correlated to the COPD severity 
based on GOLD criteria.  
SOD catalyzes the highly reactive radical superoxide into less reactive radical hydrogen 
peroxide and molecular oxygen[142]: 
O2
.− + O2
.− + 2H+  
SOD
→   H2 O2 + O2 
In humans, 3 forms of SOD have been identified: cytosolic SOD (CuZn-SOD, SOD1),  
mitochondrial SOD (Mn-SOD, SOD2), and extracellular SOD (EC-SOD, SOD3)[161]. SOD3 
which is located in the extracellular matrix (ECM) is highly expressed in lungs and 
vessels[162]. The SOD3 variants have been proved to relate to lung function decline in COPD 
patients[163]. Also the reduction of SOD3 level was found in COPD patients[164]. As SOD3 
affect lung matrix homeostasis[165] it may offer protection against pulmonary disease.  
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2 AIMS OF THE STUDY 
To elucidate the regulation of Toll-like receptor (TLR) in alveolar macrophages from healthy 
controls, smokers with and without chronic obstructive pulmonary disease (COPD), following 
stimulation with TLR ligands in combination with a glucocorticosteroid. 
 
To develop a system which combine human 3D cell models, including primary bronchial 
epithelial cells (PBEC) and fibroblasts cultured at air-liquid interface (ALI) using the XposeALI 
exposure module.  
 
To evaluate inflammatory and/ or oxidative stress effects of palladium and carbon 
nanoparticles exposure in both normal and chronic bronchitis-like lung 3D models.  
 
To further elucidate the cell-cell interactions between PBEC in PBEC-ALI models and 
macrophages upon diesel exhaust particle exposure, regarding MQ polarization, inflammatory 
and oxidative stress responses. 
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3 MATERIALS AND METHODS 
3.1 MATERIALS 
3.1.1 Cells  
3.1.1.1 Alveolar macrophages (AMQ) 
The AMQ were isolated from 10 non-allergic, non-asthmatic, non-smoking healthy controls, 
11 smokers without and 10 smokers with COPD. Detailed characterizations of the subjects and 
performance of bronchoscopy and BAL fluid has previously been described[7]. Cells from 
BAL fluid were re-suspended in 1 ml RPMI-1640 cell medium (Life technologies, Paisley, 
UK) supplemented with L-glutamine (1 %; Life technologies, Paisley, UK), penicillin 
streptomycin antibiotics (PEST, 1 %; Lonza, Basel, Switzerland) and heat-inactivated FBS (5 
%; Life technologies, Paisley, UK) and seeded into 6 well plates (0.5 million cells/well). After 
2 hours, macrophage that had adhered were cultured in 2 ml serum-free RPMI cell culture 
medium in 5% CO2 at 37ºC for 20 hours before treatment (for more details see Paper I). 
3.1.1.2 Human primary bronchial epithelial cells (PBEC) 
The PBEC were harvested from healthy bronchial tissues obtained from 10 different donors in 
connection with lung surgery (lobectomy). Such cells have been used in earlier studies[52, 166] 
and are well characterized. The PBEC were cultured in Keratinocyte serum-free medium 
(KSFM; Life technologies, Paisley, UK.) supplemented with human recombinant epidermal 
growth factor (EGF; 5 ng/ml; Life technologies, Paisley, UK), bovine pituitary extract (BPE; 
50 µg/ml; Life technologies, Paisley, UK), PEST (1 %) and retinoic acid (RA; 10-5M; Sigma, 
Germany) and maintained in 5% CO2 at 37ºC (Paper II). In Paper III and IV, for the submerged 
culturing, PneumaCult™-Ex expand medium (Stemcell technologies, Cambridge, UK) 
supplemented with hydrocortisone (96 µg/ml, Stemcell technologies, Cambridge, UK) and 
PEST (1%) was used. Culture medium was replaced every second day. The cells were used at 
passage 3 with cells from at least 3 different donors (Paper II, III and IV). 
3.1.1.3 Human fibroblast cell line (MRC-5) 
The MRC-5 is a human fetal lung fibroblast cell line (American Type Culture Collection, 
ATCC, Rockville, MD, USA), frozen at passage 24. MRC-5 cells were cultured in Dulbecco's 
modified eagle medium (DMEM; Life technologies, Paisley, UK) supplemented with HEPES 
(1 %; Life technologies, Paisley, UK), non-essential amino acids (1 %; Sigma, Germany), 
PEST (1 %) and heat-inactivated FBS (10 %) and maintained in 5% CO2 at 37ºC. Culture 
medium was replaced every second day. The cells were used at passage 26 (Paper II). 
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3.1.1.4 Human monocytic cell line (THP-1) 
The THP-1 is a human monocytic cell line derived from human blood (TIB-202™, ACTT). 
THP-1 cells were cultured in RPMI-1640 cell medium (Life technologies, Paisley, UK) 
supplemented with PEST (1 %) and heat-inactivated FBS (10 %) and maintained in 5% CO2 
at 37ºC. Culture medium was replaced every second day. When the cell concentration reached 
8 x105cells/mL, they were sub-cultured at a concentration of 1x106cells/ml (for more details 
see Paper IV). 
3.1.2 Particles generation 
3.1.2.1 Pd nanoparticles (Pd-NP) 
The Pd-NP was prepared by solvothermal technique with a modified procedure[167]. The 
formed particles were separated by centrifugation, washed by 99.5 % ethanol and dried in 
vacuum (for more details see Paper II).  
3.1.2.2 Carbon Nanoparticles (CNP) 
Endotoxin free Printex 90 particles were collected in Degussa (Frankfurt, Germany) and was a 
kind gift from Dr. Tobias Stöger´s lab (Helmholtz Centrum, Munich, Germany)[168]. The 
printex 90 particles were suspended in pyrogen free distilled water at a concentration of 20 
μg/50 μl (for more details see Paper III). 
3.1.2.3 Diesel exhaust particles (DEP) 
The DEP were generated from a three-cylinder tractor engine (Model 1113 TR; Bolinder-
Munktell) ran on diesel fuel (Swedish environment class MK 3). The exhaust, was precipitated 
and scraped from a Tepcon electrostatic filter (Model 2200; ActAir, Cardiff, UK) and stored in 
the dark at –20°C (Paper IV). 
3.1.3 Particle characterization  
3.1.3.1 Pd-NP  
Scanning electron microscope (SEM), Energy dispersive spectroscopy (EDS) (Hitachi TM 
1000-µ-DeX) and X-ray powder diffraction (multifunctional Bruker SMART Apex-II 
diffractometer) were performed to ensure Pd-NP purity and crystallinity. The individual and 
hydrodynamic (ethanol/KSFM medium) size of Pd-NP were determined by image analysis in 
transmission electron microscope (TEM) and Laser reflection microscope (Malvern Nanosight 
instrument)[167] respectively (for more detail see Paper II). 
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3.1.3.2 CNP 
Zetatrac (Model NPA151--31A; Particle Metrix GmbH, Meerbusch, Germany) was performed 
to detect the zeta potential and intensity weighted median dynamic light scattering diameter of 
Printex 90 particles (for more details see Paper III) 
3.1.3.3 DEP 
The 9-stage Marple Cascade Impactor (MCI, MSP Corporation, Minneapolis, USA) together 
with PreciseInhale™ platform (Inhalation Sciences Sweden AB, Stockholm, Sweden) were 
performed to analysis size distribution of DEP. (for more details see Paper IV) 
3.1.3.4 Endotoxin Analysis 
Limulus amebocyte lysate (LAL) assay was used to exclude the contamination of LPS in Pd-
NP, CNs and DEP. The assay was performed according to the manufacture instructions 
(Endosafe®, Charleston, SC, USA). (for more details see Paper II, III and IV) 
3.2 METHODS 
3.2.1 Stimulation of alveolar macrophages (AMQ) 
The AMQ were exposed to LPS (1µg/ml, Escherichia coli 0111: B4; Sigma, Germany), PGN 
(1µg/ml, Sigma, Germany) or TNF-α (10ng/ml; R&D SYSTEMS®, Europe, Abingdon, UK) 
with and without budesonide (Bud) (10-8 M, Sigma, Sweden). The cells were incubated in 5% 
CO2 at 37 ºC for 6 hours. Culture medium was collected and kept in -80ºC for further analysis. 
Total mRNA of AMQ was isolated (4 from healthy controls and 5 from each smoking groups). 
(Paper I) 
Monoclonal antibody (mAb) was added to block TLR2 or TLR4 (TLR2, TL2.1; TLR4, HTA 
125; eBioscience, San Diego, CA, USA), and IgG2a was used as isotype control. (Paper I) 
3.2.2 Bronchial mucosa model (3D model) establishment 
3.2.2.1 Normal 3D model  
The whole procedure took around 30 days (Table 2)[169] including cell expansion, 
establishment of the models and airlifting the models.  
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Figure 4[169] illustrates the main steps in establishing our models. To set up the models, PBEC 
were seeded at a concentration of 1×105 cell/cm2 and cultured on transwell inserts (0.4µM pore 
size, BD Falcon™) in twelve-well plate. Complete KSFM medium (with all supplements) was 
added to both basal and apical side of the insert and maintained in 5 % CO2 at 37ºC. Culture 
medium was changed every second day. After 1 week, the number of cells reached around 
3×105 cells/cm2. Then 1×104 cells/ml of fibroblasts were added to the downside of the insert 
membrane. The models were airlifted by adding airlifted medium (complete KSFM medium 
supplemented with CaCl2 in ddH2O (6 µg/ml; Sigma, Germany), ethanolamine in ddH2O (15 
ng/ml; Sigma, Germany) and RA (10-5 M)) only in the basolateral chamber to let the apical 
chamber be exposed to the air. The models were maintained in 5 % CO2 at 37 ºC and airlifted 
medium was changed every second day. (for more details see Paper II) 
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3.2.2.2 Chronic bronchitis-like 3D model  
In order to develop chronic bronchitis-like 3D models, 1 ng/ml or 10 ng/ml human IL-13 (R&D 
SYSTEMS®, UK) was added together with the airlifted medium under ALI condition. All the 
other procedures were the same as normal 3D model. (for more details see Paper II and III)  
3.2.3 Bronchial mucosa model (3D model) characterization  
3.2.3.1 Histological and immunofluorescence analysis 
For histological analysis, the model membranes were cut from insert, fixed, dehydrated, 
paraffin embedded and sectioned. The sections were stained with Hematoxylin and Eosin 
(H&E) or Periodic acid–Schiff (PAS) and captured using BX50 light microscope 
(Olympus Optical Co., Tokyo, Japan). (for more details see Paper II) 
For immunofluorescence analysis, the fixed model membranes were stained with primary 
antibodies. Mouse anti-acetylated alpha tubulin antibody was used to identify ciliated cells and 
rabbit anti-mucin 5AC antibody to identify mucus producing cells (Abcam, Cambridge, UK).  
The staining was followed by the use of secondary antibodies, Alexa Fluor® 488-conjugated 
goat anti-mouse IgG and Alexa Fluor® 555-conjugated goat anti-rabbit IgG (Abcam, 
Cambridge, UK) and then mounted on microscope slides with DAPI (Abcam, Cambridge, 
UK). Negative control slides were also prepared by excluding the primary antibodies. Images 
were captured and visualized using a LSM700 confocal microscope (Zeiss, Germany). (for 
more details see Paper II) 
3.2.3.2 Scanning (SEM) and transmission (TEM) electron microscopy  
The membranes including models were cut from inserts, fixed and dehydrated. For SEM 
analysis, the dehydrated membranes were mounted and sputter-coated for examination. For 
TEM analysis, the dehydrated membranes were embedded in LX-112 (Ladd, Burlington, USA) 
and sectioned on an ultra-microtome. Before examination the sections were contrasted with 
uranyl acetate and followed by lead citrate. (for more details see Paper II) 
3.2.3.3 Transepithelial electrical resistance (TEER) measurement 
The TEER were measured with an EVOM voltage-ohm meter and chopstick electrodes (World 
Precision Instruments, New Haven, USA). TEER= (TEER value detected - TEER value of 
insert without cells) × 0.9 (insert surface area). (for more details see Paper II) 
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3.2.3.4 Quantification analysis of specific markers  
Real-time PCR 
Fibroblasts were gently scraped from the models and the total mRNA of remaining PBEC was 
isolated by PureLink® RNA Mini Kit (Life technologies, Paisley, UK). Concentration of RNA 
was measured using the Nanodrop (ND1000 Technology). First-strand cDNA was synthesized 
with 1 μg mRNA using High-Capacity RNA-to-cDNA™ Kit (Life technologies, Paisley, UK). 
Fast SYBR® Green Master Mix (Life technologies, Paisley, UK) was used to perform the RT-
PCR with specific primers (forkhead box protein J1 (FOXJ1), MUC5AC, club cell protein 
(CC10) and Keratin 5 (KRT5)). Beta actin was adopted as an internal control gene. Data were 
analyzed using 7500 Software v.2.0.1 and results were calculated as 2-ΔCt (ΔCt = Ct (gene of 
interest) - Ct (beta actin)). (for more details see Paper II) 
ELISA 
Measurements of CXCL8 in culture medium from different models were performed using an 
in-house ELISA[170]. The detection limit was 12.5-6400 pg/ml. Levels of CC10 in culture 
medium from model were measured using a purchased DouSet ELISA uteroglobin kit (R&D 
SYSTEMS®, UK). The detection limit was 31.2 pg/ml. For all the duplicated samples, an intra-
assay variation <10 % was accepted. (Paper II) 
3.2.4 Co-cultured models including both PBEC-ALI and THP-1 derived 
macrophage (MQ)  
3.2.4.1 PBEC-ALI model 
The PBEC-ALI model was built up the same way as 3D model which was described in the 
previous section (3.2.2) but without adding fibroblasts. After submerge culturing in 
PneumaCult™-Ex expand medium, the PBEC reached confluence. Then the PBEC model was 
air-lifted by aspirating all the PneumaCult™-Ex expand medium and adding PneumaCult™-
ALI maintenance medium (Stemcell technologies, Cambridge, UK) supplemented with 
hydrocortisone (96 µg/ml), heparin (2 mg/ml Stemcell technologies, Cambridge, UK) and 
PEST (1%) to the basal chamber only. The model was kept in 5 % CO2 at 37 ºC and change 
PneumaCult™-ALI complete medium in the basal chamber every second day. (Paper III, IV) 
As for chronic bronchitis-like PBEC-ALI model (PBEC-ALI/CB), 1 ng/ml human IL-13 (R&D 
SYSTEMS®, UK) was added to the PneumaCult™-ALI medium under ALI condition. All the 
other procedures were the same as PBEC-ALI. (Paper III) 
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3.2.4.2 THP-1 derived macrophages (MQ)  
To differentiate THP-1 cell to macrophage-like cells[171], 5 ng/ml phorbol myristate acetate 
(PMA) (Sigma, Germany) was added to the culture medium[172]. After 48 hours incubation, 
the adherent cells which were supposed to be MQ were trypsinized and collected for further 
analysis. Anti-CD 68-PE-Cy7 (BD Pharmingen, San Diego, CA, United States) was used as a 
marker to detect the purity of the MQ by flow cytometry (LSR Fortessa™, BD Bioscienc, 
United States). (for more details see Paper IV) 
3.2.4.3 Co-culture of PBEC model and MQ 
MQ on top of the epithelial cells (PBEC-ALI/MQ) 
Two hundred µl THP-1 culture medium containing 1.5x105 MQ was added to the apical side 
of the PBEC-ALI model (MQ: PBEC = 1:10) and incubated in 5% CO2 at 37ºC for 2 hours. 
Before exposure, after MQ adherence, medium at the apical chamber was aspirated. (for more 
details see Paper IV) 
MQ underneath the model (PBEC-ALI/MQsub) 
After exposure, PBEC-ALI models were transferred to 12-wells plate which were pre-cultured 
with 1.5x105 MQ in the well underneath the insert with exposed PBEC and the incubation 
continued in 5% CO2 at 37ºC for 6 hours and 24 hours (For details see supplement in Paper 
IV) 
3.2.5 Exposure with XposeALI system 
Small portions of dry particle powder (Pd-NP, CNP and DEP) were generated to an aerosolized 
form and forced into the holding chamber (300ml) by compressed air (100-140 bars) using 
XposeALI system (PreciseInhale™ exposure platform). The main flow rate of generated 
aerosol was 90 ml/min (Paper II) or 120 ml/min (Paper III, IV) and divided into three 
consecutive branch flows of 10 ml/min for each exposure of triplicate model inserts at the same 
time. Models were exposed for different time durations in proportion to the desired target dose. 
Corresponding to low, medium and high exposure doses, the exposure cycles took 20 seconds, 
45 seconds, 3 minutes (Paper II), and 1 minutes, 2 minutes, 3 minutes (Paper III). and 15 
seconds, 45 seconds, 3 minutes (Paper IV). As a control, sham exposures was performed with 
identical settings using normal air and a clean exposure system.   
After aerosol exposure, the models were incubated in 5 % CO2 at 37 ºC for 6 hours (Paper III), 
8 hours (Paper II) or 24 hours (Paper II, III, IV). The apical medium (AM) was obtained by 
lavage on apical side of the epithelial layers for 15 minutes at room temperature (Paper II, III). 
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Both AM (Paper II, III) and medium from the basal chamber of the insert (BM) (Paper II, III, 
IV) were collected and frozen at -80 ºC until further use. 
3.2.6 Particle exposure dose and uptake  
3.2.6.1 Particle exposure dose 
To determine Pd-NP exposure doses, the model membranes were digested by aqua regia and 
neutralized to pH=3 by ammonia after exposure. Analyses were carried out by inductively 
coupled plasma mass spectrometer (ICP-MS)[173] with an isotopically enriched 108Pd as 
standard. (for details see Paper II). 
As for CNP and DEP exposure doses, after particle exposure, the membranes including models 
were rinsed with 99% ethanol. Analysis were carried out by spectrophotometer technique (Cary 
60 UV-Vis, Agilent Technologies, Palo Alto, CA, United States). The gradient diluted CNP or 
DEP in 99% ethanol were recognized as standard (Paper III and IV). 
The actual exposure dose of Pd-NP, CNP and DEP in each insert (PI) was calculated using the 
following formula: 
Particle expoure dose =
PI
IS (insert surface area) 
 
3.2.6.2 Particle exposure uptake  
The localization of the particles in models were detected by TEM (section 3.2.3.2) after 
incubation for 2, 4, 8 and 24 hours post Pd-NP exposure. (for details see Paper II)  
To identify the uptake of DEP by MQ, a commercial quadri-wave lateral shearing 
interferometry (QWLSI) (SID4Bio, Phasics SA, Saint Aubin, France) was directly plugged 
onto microscope (Labphot-2, Nikon FX-35DX) to detect distribution of mass across the models 
(Paper IV).  
3.2.7 Assessment of cytotoxicity 
3.2.7.1 Trypan blue assay 
To determine viability of the cells, trypan blue was used to assess cell membrane integrity. For 
re-suspended cells or cells after trypsinization, 10 µl 0.4% trypan blue was mixed with 10µl 
cell suspension, and 200 cells were counted to calculate the viability (Paper I-IV). For the 
models, before and 8/24 hours after exposure, 200 µl 0.2% trypan blue was added to the apical 
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side of the insert. Four fields of the insert were randomly selected and in each filed 200 cells 
were counted (Paper II, IV). Viability of more than 95% was acceptable.  
3.2.7.2 Lactate dehydrogenase (LDH) assay 
Cell viability was estimated based on the measurement of LDH which is a cytosolic enzyme 
released into cell culture medium when plasma membranes are damaged. After exposure 50 µl 
of BM were assayed for LDH activity following the manufacturer´s protocol. Results were 
presented as % Cytotoxicity = Particle exposed LDH activity – Spontaneous LDH activity / 
Maximum LDH activity – Spontaneous LDH activity. (Paper III and IV) 
3.2.7.3 Alamar Blue Assay  
To confirm the cell viability further Alamar Blue® Assay which is based on the detection of 
metabolically active cells was performed. The assay utilizes changes of the fluorescence of 
resazurin (blue, non-fluorescent) to the reduced form resorufin (red, highly fluorescent). Four 
hundred μl of 10% Alamar Blue® solution was added to the apical side of the model and 
collected after 2 hours. The absorbance was measured using spectrophotometer at an emission 
of 570 nm with 600 nm as a reference wavelength. (Paper III) 
3.2.7.4 Apoptosis assay 
After 6/8/24 hours culturing post exposure, models were trypsined and treated with annexin 
V–PE/7-AAD according to the manufacturer's instructions (BD Pharmingen, San Diego, CA, 
United States). Apoptotic cells were detected by collecting 2000 cells using flow cytometry 
(LSR Fortessa™, BD Bioscienc, United States) (Paper II-IV). 
3.2.8 Measurement of inflammatory, oxidative stress and MQ polarization 
markers 
3.2.8.1 Analysis of mRNA 
In Paper I, after stimulation, AMQ mRNA from 4 healthy controls and from 5 smokers with 
and without COPD group were isolated by PureLink® RNA Mini Kit (Life technologies, 
Paisley, UK). First-strand cDNA was synthesized with 0.5 μg mRNA using QuantiTect® 
Reverse Transcription Kit (Qiagen NV, Venlo, the Netherlands). Fast SYBR® Green Master 
Mix (Life technologies, Paisley, UK) was used to perform the RT-PCR with primers (TLR2 
and TLR4).  
In Paper III and IV, after 6/24 hours culturing post exposure, models were lysed. Total mRNA 
was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany). The following steps were 
the same as described in section 3.2.3.4. Primers of genes involved in pro-inflammation 
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(CXCL8, IL6 and TNFα), innate immunity (TLR2 and TLR4), tissue injury/repair (MMP9 and 
TIMP1), oxidative stress (NFKB, HMOX1, GPx, SOD3 and GSTA1), and macrophage 
polarization (M1; IL23, IL12, M2; IL4, IL10, IL13, MRC1, MRC2, RETNLA) was used.  
For all the analysis, beta actin was adopted as an internal control gene. The data were analyzed 
using 7500 Software v.2.0.1, and results were calculated as 2-ΔCt (ΔCt = Ct (gene of interest) - 
Ct (beta actin)). (Paper I, III and IV). 
3.2.8.2 Analysis of protein levels 
Flow cytometry 
For PBEC-ALI, the expression of TLR2 and TLR4 were detected directly using anti-TLR2 and 
anti-TLR4 monoclonal antibodies (anti-TLR2-APC, anti-TLR4-PE, BD Pharmingen, San 
Diego, CA, United States). For PBEC-ALI/MQ, cells were treated with CD68 monoclonal 
antibody (anti-CD 68-PE-Cy7; BD Pharmingen, San Diego, CA, United States) to distinguish 
between PBEC and MQ in co-cultured model. Then TLR2 and TLR4 expression were detected 
in PBEC (CD68 –) and MQ (CD68+) respectively. For all the detection, unstained cells were 
used to gating the positive populations[174]. Analyses were performed using flow cytometry 
(LSR Fortessa™, BD Bioscienc, United States) and calculated as median fluorescence intensity 
(MFI). (Paper IV) 
ELISA 
Concentrations of IL-6 and CXCL-8 in AM/BM were measured using the in-house ELISA 
method described previously[170]. Commercially available antibodies (R&D SYSTEMS®, 
UK) were used. The detection range was 3-375 pg/ml for IL-6 and 12.5-6400 pg/ml for CXCL-
8. MMP-9, TIMP-1, CC-10, TGF-β, IL-13 and IL-10 in AM/BM were measured using 
purchased DouSet ELISA Kit (R&D SYSTEMS®, UK). The detection limit was 31.2 pg/ml 
for all the DouSet ELISA. The measurements of TNF-α in BM were performed by purchased 
DouSet or HS quantikine ELISA Kit (R&D SYSTEMS®, UK). The detection limit was 7.8 
pg/ml for DouSet and 0.049 pg/ml for HS quantikine ELISA. All the analyses were performed 
according to the manufacturer. For all the duplicated samples, an intra-assay variation <10 % 
was accepted (<20 % for TNF-α HS quantikine ELISA).  
3.2.9 Statistics  
Depending on the distribution of the data, the results are presented as mean values and 95 % 
confidence interval (95% CI) or median values and 25th–75th percentiles.  
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As the sample size was small in all studies, also the distribution was not clear for every 
outcome, non-parametric statistical methods were used in this thesis (except lung function 
index in Paper I). The comparison between groups, were performed by Kruskal–Wallis test 
followed by the Mann–Whitney U-test as a post hoc test (Paper I). The comparisons within 
groups (Paper I) or between different models (Paper II-IV) were assessed by Friedman test if 
more than 2 groups followed by Wilcoxon signed rank t test as a post hoc test or Wilcoxon 
signed rank test direct if only 2 groups. A p-value <0.05 was considered as significant. All the 
data were analyzed using STATISTICA9 (StatSoft, Inc. Uppsala, Sweden).  
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4 RESULTS 
4.1 PAPER I 
In Paper I, the aim was to explore whether TLR ligands alter Toll-like receptor expression 
(TLR2, TLR4) and to what extent a glucocorticosteriod interacts with this ligand-receptor 
interaction on immune effector cells.  
The experiments were performed on alveolar macrophages (AMQ) isolated from BAL-fluid 
from healthy controls and smokers with and COPD. The AMQ were stimulated with 
peptidoglycan (PGN), lipopolysaccharide (LPS), or TNF-α with and without the addition of 
budesonide (Bud). The TLR2 or TLR4 blocking antibodies were also added before identical 
stimulations. The levels of secreted pro-inflammatory cytokines and chemokines as well as 
mRNA expression of TLR2 and TLR4 were measured after all different stimulations. 
For further details, see paper I. All the figures have been published and permitted to be used 
here[175]. 
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In AMQ from all three groups LPS and PGN stimulation enhanced IL-8/CXCL-8 and TNF-α 
secretion which was attenuated by Bud (except PGN-induced IL-8/CXCL-8 release in smokers 
without COPD) (Figure 5B&C; Figure 6B&C). TNF-α increased the release of IL-8/CXCL-8 
in AMQ from healthy controls and smokers without COPD which was inhibited by Bud in the 
latter group (Figure 5D).  
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As for TLR mRNA expression, Bud itself increased TLR2 mRNA expression in non-smokers 
and smokers without COPD (Figure 7A). The combination of Bud and TLR ligands (PGN or 
LPS) also increased TLR2 mRNA expression in smokers with and without COPD (Figure 
7B&C). Further, stimulation with LPS decreased the transcript expression of TLR4 in all three 
groups (Figure 8B).  
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To identify whether the inflammatory effects of a stimulus are driven by TLR pathways, TLR2 
and TLR4 were blocked by corresponding antibodies. The TLR-blockade tended to inhibit 
PGN and LPS induced IL-8/CXCL-8 secretion in all three groups (Figure 9).   
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4.2 PAPER II 
In Paper II, the aim was to develop an advanced system consist of 3D model and a sophisticated 
exposure platform to resembles an in vivo situation.  
The 3D model was built by human primary bronchial epithelial cells (PBEC) and a fibroblast 
cell line co-cultured under air liquid interface (ALI). To validate the 3D model and to clarify 
how PBEC differentiate under ALI culture condition, light-, confocal microscopy, scanning-, 
and transmission electron microscopy, RT-PCR, ELISA and TEER were performed. Trypan 
blue and FACS were used to identify cell viability and apoptosis rate in the models. To build 
chronic bronchitis-like 3D model, 1ng/ml IL-13 was added at the start of air-lifting.   
After establishment, both normal and chronic bronchitis-like 3D models were exposed to 
custom synthesized size-uniform palladium nanoparticles (Pd-NP) at three different 
concentrations with XposeALI system and then incubated for 8 and 24 hours. Exposure to 
normal air and clean system served as a control. Levels of IL-8/CXCL-8 and MMP-9 were 
detected from apical lavage medium (AM) and basal medium (BM).  
For further details, see paper II. All the figures have been published and permitted to be used 
here[169]. 
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According to hematoxylin and eosin (H&E) staining analyses of cross sections of normal 3D 
model (Figure 10A), we found that PBEC build up a pseudo-stratified cell layer on the insert 
membrane and differentiate into basal cells, club cells, mucus producing cells and ciliated cells. 
Immunofluorescence analysis (Figure 10B), confirmed that 3D model contained ciliated cells 
which were covered by multiple cilia (green florescence) as well as mucus producing cells 
which can be stained with MUC5AC antibody (red florescence). The SEM (Figure 10C) and 
TEM (Figure10D&E) analyses were performed to identify appearance and ultra-structure 
architecture of PBEC in 3D model. Ciliated cell surface was scattered with elongated cilia 
which showed axonemes consisting of two central singlet and nine outer doublet microtubules. 
Mucus producing cell showed an electron-dense cytoplasm that contained electron-lucent 
granules.  
The mRNA expressions of different cell type specific markers (FOXJ 1 indicated ciliated cells, 
MUC5AC indicated mucus producing cells, Club cell protein indicated club cells and KRT5 
indicated basal cells) with different culture time points were detected by RT-PCR (Figure 11). 
From the results, the FOXJ1 mRNA expression was significantly higher after being airlifted 
for 2 or 3 weeks compared to 1 week. However, there is no significantly changes for mRNA 
expressions of MUC5AC, Club cell protein and KRT5 over time.  
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Treating airway epithelial cell with IL-13 induces mucus producing cell metaplasia and 
hyperplasia as well as increased mRNA expression of MUC5AC[132]. Therefore, different 
concentrations of IL-13 were tested to build up chronic bronchitis-like 3D model. We found 
that stimulation of the model with IL-13 increased MUC5AC mRNA expression (Figure 12A). 
Based on PAS stained cross sections (Figure 12B), model treated with IL-13 (1 ng/ml and 10 
ng/ml) have more mucus producing cells than untreated model. However, with 10 ng/ml IL-13 
treatment, almost all cells in the model produced mucus, which does not represent the real 
situation in vivo. Therefore, we used 1 ng/ml IL-13 to build chronic bronchitis-like 3D model. 
After treatment, the model contained different types of cell with more mucus producing cells. 
The TEER reached 192±37 Ω.cm2 and 187±55 Ω.cm2 in the normal and chronic bronchitis-like 
3D models respectively, with no significant differences in barrier integrity between normal and 
chronic bronchitis-like 3D models (Data not shown). 
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The particles used in this study were proved to be high purity Pd metal by X-ray diffraction 
and EDS analysis (Figure 13A&B). The Pd-NP was agglomerated when drying, but easily 
formed a uniform aerosol with a narrow size distribution between 6–10 nm (Figure 13C). The 
hydrodynamic size of Pd-NP in ethanol and KSFM medium were 138±3 and 151±6 nm, 
respectively (Figure 13E&F).  
The Pd-NP exposure dose in the model was analyzed by ICP-MS and the three doses of Pd-NP 
used were 250 ng/cm2 (low), 400 ng/cm2 (medium) and 650 ng/cm2 (high). After Pd-NP 
exposure with XposeALI system, we found most of the Pd-NP immobilized on the cell surface 
with a few Pd-NP inside the cells, and there were no differences between different incubation 
time post exposure (Figure 13G). Interestingly, after exposure, Pd-NP were spread evenly on 
the cell surfaces (Figure 13H), but after 24 hours of incubation, the Pd-NP were redistributed 
and accumulated at one spot (Figure 13I). This phenomenon may indicate an existing 
mucociliary clearance effect of the model.   
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Before and after exposure, a viability of models above 95 % is accepted. The apoptotic rate 
was 1 -30 % with no difference between sham and Pd-NP exposure neither between different 
normal nor different chronic bronchitis-like 3D models. 
After 24 hours incubation post Pd-NP exposure, the level of IL-8/CXCL-8 in BM from chronic 
bronchitis-like 3D model was higher than normal model (Figure 14B). The same pattern was 
shown in BM from unexposed model. There was a tendency of Pd-NP dose-dependently 
increase of BM IL-8/CXCL-8 secretion after 8 hours incubation in both normal and chronic 
bronchitis-like 3D models (Figure 14A). However, after 24 hours incubation, this tendency 
only persisted in chronic bronchitis-like 3D model (Figure 14B). The BM level of IL-8/CXCL-
8 was significantly higher after 24 hours incubation than after 8 hours (Figure 14A&B), while 
there was no difference between these two time points regarding AM IL-8/CXCL-8 levels 
(Figure 14C&D). Worth mentioning in all models, after Pd-NP exposure, the release of MMP-
9 in BM were significantly lower than in AM (data not shown). 
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4.3 PAPER III 
In Paper III, the aim was to investigate the inflammatory and oxidative stress responses to 
exposure to aerosolized carbon nanoparticles (CNP) in normal and chronic bronchitis-like 
models (IL-13 induced) using physiologically relevant primary bronchial epithelial cells 
(PBEC) developed air liquid interface (ALI) in vitro model. 
The PBEC were cultured at ALI and considered as normal model (PBEC-ALI), and 1 ng/ml 
IL-13 treatment was used to develop chronic bronchitis-like model (PBEC-ALI/CB). 
XposeALI exposure system was used to perform 3 different doses of CNP exposure. Exposure 
to normal air and clean system served as a control. After 6 hours and 24 hours poster exposure, 
the protein levels of CXCL-8 and MMP-9 in BM were detected by ELISA. Transcript 
expression of pro-inflammatory, oxidative stress and tissue injury/repair markers were assessed 
by RT-PCR.  
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In PBEC-ALI, CXCL-8 secretion was significantly increased at 24 hours post exposure to CNP 
(high dose) compared to sham exposure (Figure 15A, left panel). In PBEC-ALI/CB, 24 hours 
exposure to the two highest doses of CNP resulted in increased CXCL-8 secretion compared 
to sham exposure (Figure 15A, right panel). As for the secretion of MMP-9, in PBEC-ALI, 
MMP-9 levels in BM were increased significantly at 24 hours following exposure to both 
highest doses of CNP (Figure 15B, left panel). Additionally, CXCL-8 secretion was 
significantly increased after exposure to sham and the two highest doses of CNP in PBEC-
ALI/CB model compared to corresponding PBEC-ALI model (Figure 15A). In PBEC-ALI/CB 
exposure to sham induced a higher release of MMP-9 levels compared to sham exposed PBEC-
ALI 24 hours post exposure (Figure 15B, left panel). At 6 hours following CNP exposure, both 
CXCL-8 and MMP-9 levels remained unchanged at all CNP doses in both PBEC-ALI and 
PBEC-ALI/CB (data not shown).  
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Transcript expression of pro-inflammatory markers (CXCL8, IL6, TNFα, NFKB; Figure 16) 
and oxidative stress genes (HMOX1, SOD3, GSTA1, GPx; Figure 17) were assayed from both 
PBEC-ALI and PBEC-ALI/CB models at 6 hours and 24 hours post exposure to sham and 
aerosolized CNP at 3 different doses. Exposure to aerosolized CNP resulted in increased 
transcript expression of CXCL8, IL6 and TNFα after 6 hours in PBEC-ALI/CB (highest dose 
vs sham; Figures 16A-C, right panel). Additionally, 24 hours following exposure to CNP in 
the PBEC-ALI, the mRNA expressions of IL6 and TNFα were significantly increased (low and 
medium doses vs sham; Figure 16F&G, left panel), while expressions of CXCL8 and NFKB 
remained unaltered after exposure to any CNP doses (Figure 16E&H, left panel). Only HMOX1 
transcript expression was increased 6 hours post CNP exposure in the PBEC-ALI/CB (low and 
high doses vs sham; Figure 17A, right panel). After 24 hours culturing, expression of HMOX1 
(low dose vs sham; Figure 17E, left panel) as well as SOD3 and GSTA1 (all three doses vs 
sham; Figure 17F&G, left panel) were induced by CNP exposure in PBEC-ALI. 
After both 6 hours and 24 hours following CNP exposure, CXCL8 expression increased more 
in PBEC-ALI/CB compared to PBEC-ALI (sham, medium and high doses, Figure 16A&E). 
Also, IL6 mRNA expression was significantly higher in PBEC-ALI/CB compared to PBEC-
ALI 6 hours after exposure to both sham and CNP at all 3 different doses (Figure 16B). Besides, 
CNP exposure induced a higher expression of TNFα in PBEC-ALI/CB than in PBEC-ALI (6 
hours, medium and high dose; 24 hours, low and high dose; Figure 16C&G). The mRNA 
expression of HMOX1 was significantly higher in PBEC-ALI/CB compared to PBEC-ALI 
after exposure to both sham and CNP at all 3 different doses (Figure 17A). As for SOD3, an 
enhanced mRNA expression in PBEC-ALI/CB compared to PBEC-ALI could only be found 
6 hours post sham exposure (Figure 17B), while a decreased expression 24 hours post CNP 
exposure (medium and high doses; Figure 17F) where observed in PBEC-ALI/CB compared 
with PBEC-ALI. Both GSTA1 and GPx were significantly increased 6 hours after CNP 
exposure at the two lowest doses in PBEC-ALI/CB compared with PBEC-ALI (Figure 
17C&D). 
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Six hours after exposure to the two highest doses of CNP the expression of MMP9 were 
significantly upregulated in PBEC-ALI/CB while corresponding TIMP1 expression did not 
change (Figure 18A&B, right panel). After 24 hours culturing the expression of both MMP9 
and TIMP1 increased significantly after exposure to the two lowest doses of CNP in PBEC-
ALI (Figure 18C&D, right panel). After 6 hours post-exposure to both sham and all three 
concentrations CNP exposure, resulted in a significantly higher MMP9 expression in PBEC-
ALI/CB compare to PBEC-ALI (Figure 18A).  
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4.4 PAPER IV 
In Paper IV, the aim was to build multi-cellular model consisting of human primary bronchial 
epithelial cells (PBEC) cultured at ALI with and without the addition of macrophages (MQ, 
THP-1 cell differentiated macrophage), followed by diesel exhaust particles (DEP) exposure 
to identify crosstalk between airway epithelial cells and MQ.  
The PBEC cultured at ALI were co-cultured without (PBEC-ALI) and with MQ (PBEC-
ALI/MQ).  The models were exposed to aerosolized DEP using XposeALI. Exposure to normal 
air and clean system served as a control. The CXCL8 and IL-6 were measured in BM by 
ELISA. The mRNA expression of inflammatory, oxidative stress and MQ polarization markers 
were measured by RT-PCR. The surface/mRNA expression of TLR2/TLR4 was detected by 
FACS and RT-PCR, respectively. 
For further detail see paper IV. All the figures have been published and permitted to be used 
here[176]. 
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According to a 9-stage Marple Cascade Impactor analysis, the mass median aerodynamic 
diameter (MMAD, P50) of DEP aerosols used in this study was 0.57µm (Figure 19A). After 
XposeALI exposure, the SEM figures indicated an evenly distribution of DEP with similar 
agglomerated structure as previous reported[177] (Figure 19B). The DEP is free form LPS 
based on results from LAL testing (data not shown). By plugging Quadri-Wave Lateral 
Shearing Interferometry (QWLSI) onto microscope, we found, clearly distinguished from 
epithelial cells, MQ that appeared contrasted with some dense parts which may indicate the 
engulfment of DEP particles (Figure 19C). The dose of DEP after exposure was detected by 
rinsing the exposed insert with 99% ethanol and detecting with spectrophotometric technique. 
The DEP dose in this study was 3.4 (low), 5 (medium) and 12.7 (high) µg/cm2 respectively.  
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The secretion of CXCL-8 (Figure 20A) and IL-6 (Figure 20B) and the mRNA expression of 
HMOX1(Figure 21B) and GPx (Figure 21C) were upregulated, while IL6 (Figure 20D) and 
TNFα (Figure 20E) transcript were downregulated in PBCE-ALI/MQ compared to PBEC-ALI 
as a consequence of sham exposure. In PBEC-ALI, CXCL-8 (Figure 20A) and TIMP-1(Figure 
22B) secretion as well as CXCL8 (Figure 20C), TNFα (Figure 20E), NFKB (Figure 21A), 
HMOX1 (Figure 21B) and GPx (Figure 21C) mRNA expression were significantly increased 
after DEP exposure compared to sham exposure. The secretion of TIMP-1 (Figure 22B) and 
the expression of CXCL8 (Figure 20C), TNFα (Figure 20E), NFKB (Figure 21A) and HMOX1 
(Figure 21B) were decreased in PBEC-ALI/MQ compared to PBEC-ALI indicating that MQ 
attenuate the effects of DEP exposure. The levels of TNF-α secretion were under detection 
limit (data not shown). 
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The mRNA expressions of TLR2 and TLR4 were increased by DEP exposure in PBEC-ALI 
(Figure 23).  
The surface expression of TLR was detected by FACS.  As mentioned in section 3.2.8.2, anti-
CD68 antibody was used to distinguish between PBEC (CD68-) and MQ (CD68+) in PBEC-
ALI/MQ model. The ratio of PBEC and MQ was 10:1(data not shown) which was the same 
ratio as we seeded. Then TLR2 and TLR4 surface expressions on PBEC and MQ were detected 
separately with FACS analysis (Figure 24). Sham exposure attenuated TLR2 and TLR4 surface 
expression on PBEC in PBEC-ALI/MQ than in PBEC-ALI (Figure 24A(c)&(d)) while there 
was no such alternation after DEP exposure. In PBEC-ALI, the PBEC surface expression of 
TLR4 decreased after DEP exposure compared to sham exposure (Figure 24A(d)). When co-
cultured with MQ, the PBEC surface expression of TLR4 decreased while TLR2 increased 
after DEP exposure compared with sham exposure (Figure 24A(c)&(d)). As for MQ in PBEC-
ALI/MQ, DEP exposure led to the same surface expression pattern of TLR2 and TLR4 as 
PBEC (Figure 24B(c)&(d)).  
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The IL4 (Figure 25B), MCR1 (Figure 25D), MRC2 (Figure 25E), and RETNLA (Figure 25F) 
mRNA expression increased more in PBEC-ALI/MQ compared to PBEC-ALI following DEP 
exposure. The DEP exposure increased all M2 macrophage transcription markers except 
RETNLA compare with sham exposure in PBEC-ALI/MQ (Figure 25). Exposed MQ mono-
culture only with after DEP exposure did not alternate mRNA expression of M2 macrophages 
markers (data not shown). 
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5 GENERAL DISCUSSION  
The lungs are continuously exposed to a wide variety of airborne particles, antigens and toxins 
that affects human immune system leading to innate and adaptive immune responses as well 
as pro-inflammatory, anti-inflammatory and oxidative stress reactions. On one hand, lung 
serves as the primary port of entry for inhaled agents implying risk of development of 
pulmonary diseases. On the other hand, the lungs also are easily accessible for targeted drug, 
like bronchodilators and glucocorticosteroids.  
The main objective of this thesis was to develop physiological relevant multi-cellular models 
of normal and chronic bronchitis-like airway mucosa in order to study cell-cell interactions, 
inflammatory and oxidative stress mechanisms induced by exposures to different 
particles[169]. We used immune competent cells like macrophages and structural cells like 
epithelial cells both ex vivo and in vitro and exposed them to different organic material and 
ultrafine or nanoparticles. A second focus was to explore innate immune responses by studying 
Toll-like receptors and how they can precisely modulate cellular inflammatory responses.    
5.1 CELL CULTURE MODELS 
The Swedish government has commissioned several agencies to draw up strategies for 
replacement, reduction and refinement (3R) of animal experiments according to the regulatory 
letter of 2016. The 3R is also taken into account during evaluation of substances within the 
European chemical regulation REACH, and 3R must comply with the requirements in 
DIRECTIVE 2010/63/EU on the protection of animals used for scientific purposes. Because 
of these novel instructions development and evaluation of advanced and realistic ex vivo and 
in vivo-like lung models at different levels are urgently needed. 
Alveolar macrophage (AMQ) are the major immune-competent cell population in human lung 
[29] and their main function are to recognize potential pathogens or toxins entering into the 
lung[178]. They orchestrate airway inflammation by production of different kinds of cytokines 
and chemokines. Studies from our group have shown that the number of macrophages in 
bronchoalveolar lavage (BAL) are elevated in smokers without and with COPD compared with 
non-smokers[179], and that the number of macrophages was associated with the degree of 
severity of COPD[180]. Therefore, in Paper I, we isolated AMQ from BAL fluid from non-
smokers and smokers with COPD and stimulated the AMQ ex vivo to elucidate how Toll-like 
receptors (TLR) expression is altered following exposure to different stimuli.  
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Due to the new directives physiologically relevant in vivo-like model systems are becoming 
increasingly interesting for studying molecular mechanisms of pulmonary diseases. As lung is 
a primary contact organ, bronchial epithelial cells under air-liquid interface (ALI) conditions 
resemble the airway wall as far as baso-apical orientation, ciliation and mucus production is 
concerned. In Paper II and Paper III we established airway mucosal 3D model by human 
primary bronchial epithelial cells (PBEC) and cultured them at ALI with and without 
fibroblasts, which allows the model to differentiate into ciliated cells, mucus producing cells, 
club cells and basal cells. By the addition of IL-13, a chronic bronchitis-like model containing 
increased numbers of mucus producing cells was built. Both models can mimic the bronchial 
epithelium in health and disease conditions in vivo to study the toxicity of inhaled substances. 
Mono-culture of epithelial cells or macrophages responded differently to xenobiotics when 
compared with co-cultures these cell types[181]. In both upper and lower airways, macrophage 
abundantly reside along the epithelium, and facilitate interaction with bronchial epithelial 
cells[182]. The cell to cell contacts of macrophage and epithelium are very important in 
modulating macrophage phenotype and function[183]. In a pilot study included in Paper IV, 
we exposed the PBEC-ALI models to DEP and then co-culturing with MQ placed underneath 
the models. However, in these models where MQ and PBEC-ALI had no direct contact, but 
only indirectly with possibility to communicate through mediators, we did not see any effect 
of the presence of MQ after DEP exposure. Hence, the direct contact between the two types of 
cells seems very important in response to particle exposure. Therefore, in Paper IV, when 
culturing MQ on the apical surface of epithelial cell which allows direct contact between the 
two cell types, mimics the in vivo situation and enables crosstalk between the cells. 
5.2 DIFFERENT STIMULI 
Chronic exposure to inhaled agents such as cigarette smoke, ambient dust, and particulate 
matter (PM) from traffic emissions or air pollution is associated with pulmonary and systemic 
inflammation which eventually may result in pulmonary injuries. Pathogen-associated 
molecular patterns (PAMPs) such as lipopolysaccharide (LPS) from endotoxin of Gram-
negative bacteria and peptidoglycans (PGN) from Gram-positive bacteria constitute pro-
inflammatory stimuli and  may cause airway inflammation[52]. Nanoparticles are more potent 
pro-inflammatory stimuli and induce more cell damage than the same material of larger 
size[184]. Because their high lung deposition efficiency and great specific surface area[185, 
186], they can combine with other substances to avoid the pulmonary clearance and 
subsequently cause respiratory toxicity. Exposure to nanoparticles like Pd-NP and CNP have 
been shown to induce cardiovascular, pulmonary or renal impairments in rodent models[168, 
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187]. Further, particles like DEP which are the products of diesel engine fuel incomplete 
combustion, has also been recognized as a risk factor for chronic bronchitis[188]. Both acute 
and chronic exposure to DEP can not only cause, but also increased the mortality of COPD/ 
asthma exacerbation, cardiovascular disease and respiratory infections[189-191]. Therefore, in 
this thesis, we exposed different cell cultures including AMQ ex vivo culture, normal/ chronic 
bronchitis-like 3D models (with and without fibroblast) and finally PBEC and MQ co-cultured 
models to these environmental stimuli (LPS, PGN, Pd-NP, CNP and DEP) in order to figure 
out the inflammatory and oxidative stress implement of these stimuli described above.  
5.3 INFLAMMATORY AND OXIDATIVE STRESS RESPONSE  
In macrophages (Paper I) we found that PGN and LPS significantly increased the secretion of 
CXCL-8 and TNF-α which were attenuated by budesonide in AMQ from healthy controls and 
smokers with and without COPD (one exception in smokers without COPD). This finding was 
in line with previous results from our group, where  LPS, PGN and TNF stimulations of PBEC 
increased the release of CXCL-8 and IL-6, which was reduced by the addition of 
budesonide[52]. Budesonide is a glucocoticosteroid frequently used alone or in combination 
with β2-agonists in the treatment of asthma and COPD. Budesonide binds to the 
glucocoticosteroid receptor (GR) which is located in the cytosol. The GR-glucocoticosteroid 
complex then enters the nucleus and may take two paths, either activate anti-inflammatory gene 
transcription or inhibit pro-inflammatory gene transcription[19]. Hence, budesonide induced 
inhibition of LPS and PGN induced inflammatory responses could either be caused by 
switching off multiple inflammatory gene and inhibiting the translocated of transcription 
factors from cytoplasm to nucleus or switch on anti-inflammatory gene. Interestingly, in Paper 
I, both control and PGN-treated AMQ from smokers without COPD produced more CXCL-8 
than healthy controls. Also Bud attenuate the TLR-ligand induced CXCL-8 secretion with the 
same exception in PGN-treated AMQ from smokers without COPD. These results may indicate 
that AMQ form smokers without COPD are more active and less glucocoticosteroid sensitive 
than AMQ from healthy controls.  
In epithelial cells we detected inflammatory and oxidative stress responses to different particle 
(Pd-NP, CNP and DEP) exposures in all models used (PBEC-ALI, PBEC-ALI/CB and PBEC-
ALI/MQ models) (Paper II-IV). We found increased secretion of CXCL-8, as well as increased 
mRNA expression of CXCL8, TNFα, and NFKB 24 hours post exposure of PBEC-ALI to DEP 
(Paper IV). Similarly, previous studies showed that DEP exposure increased the levels of 
CXCL-8, IL-6 and TNF-α in human alveolar epithelial ALI models and in epithelial cell 
lines[192-194]. The Pd-NP and CNP aerosol exposure dose-dependently increased CXCL-8 
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release in basal medium after 24 hours in chronic bronchitis-like model (Paper II&III). This is 
in line with our previous study that showed increased secretion of CXCL-8 at the highest 
concentration of culture medium dispersed Pd-NP when culturing PBEC at submerge condition 
[167]. Also one study identified similar significant dose-dependent increase of CXCL8 
expression in A549 cells after 24 hours of exposure to CNP[195]. Interestingly, in Paper III, 
we showed that at 6 hours following CNP exposure, IL6 and TNFα expression was upregulated 
in PBEC-ALI/CB model, while at 24 hours following CNP exposure such increase was only 
found in PBEC-ALI. We conclude that the pro-inflammatory effect following CNP exposure 
seem to appear at an earlier stage in the PBEC-ALI/CB than in PBEC-ALI. Although, the 
induction of IL6 mRNA expression or TNFα secretion upon CNP exposure has been studied 
in animal model[168, 196], this time dependent regarding pro-inflammatory response and 
PBEC-ALI/CB respond earlier seems rarely been reported.  
It is well known that both CNP and DEP can induce an production of ROS[197-199]. The 
excessive ROS production challenges the cellular homeostasis by disturbing the balance 
between ROS and antioxidant production. The ROS may trigger the translocation of Nrf2 and 
subsequently, hetero-dimerized with antioxidant response elements (ARE) in the nucleus. In 
combination with other transcription factors, the Nrf2/ARE complex induced the expression of 
antioxidant genes like HMOX1, SOD3, GSTA1and GPx[200]. Zarcone et al identified that 
exposure to DEP induced stress responses in PBEC ALI culture[201]. Consistently, in Paper 
III&IV, we found increased mRNA expression of antioxidant genes (HMOX1, SOD3 and 
GSTA1 upon CNP exposure; HMOX1 and GPx upon DEP exposure) in PBEC-ALI 24 hours 
post CNP and DEP exposure. Interestingly, the induction of HMOX1 transcript expression after 
6 hours post exposure CNP exposure can only be found in PBEC-ALI/CB, which was similar 
as pro-inflammatory response (Paper III).  
By adding Th2 cytokines like IL-13, the bronchial epithelial cells differentiate further and 
the number of mucus-producing cells and MU5AC production increased, which are 
characteristic features of chronic bronchitis[44, 202]. Also IL-13 expression is increased in 
central airway of smokers with chronic bronchitis[134]. Besides, in Paper II, we showed that 
IL-13 treatment (1 ng/ml) increased mucus-producing cell and MU5AC mRNA expression 
in our chronic bronchitis-like 3D model. Thus, we regard the models treated with IL-13 
representing chronic bronchitis conditions (Paper II&III). We found that CXCL-8 secretion 
levels were higher in chronic bronchitis-like models than normal models 24 hours after sham 
and Pd-NP or CNP exposure. This could be an expression of more activated cells in the 
chronic bronchitis-like model. Also, it is possible that mucus-producing cells can produce 
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more CXCL-8 than ciliated cells, since there were a higher proportion of mucus-producing 
cells in chronic bronchitis-like mucosa model. This could be an explanation why the chronic 
bronchitis-like models secreted more CXCL-8 than normal models. Additionally, stimulation 
with IL-13 could also contribute by itself and not only indirectly by increasing the number 
of mucus-producing cells causing increased CXCL-8 production. In Paper III, the transcript 
expressions of inflammatory and oxidative stress genes were upregulated in PBEC-ALI/CB 
compared to PBEC-ALI. As mentioned above, the induced mRNA expressions of 
inflammatory and oxidative stress were mostly found after 6 hours of exposure to CNP in 
PBEC-ALI/CB, while in PBEC-ALI, the increasing effects were more pronounced after 24 
hours post CNP exposure (Paper III). From these data it may be assumed that PBEC-ALI/CB 
generally react faster and stronger than PBEC-ALI to external stimuli. Furthermore, in Paper 
III, at 6 hours post CNP exposure, MMP9 expression was significantly higher in the PBEC-
ALI/CB compared to PBEC-ALI, while TIMP1 expression was not altered. This suggest that 
the PBEC-ALI/CB does not counteract the increased expression of the matrix degradation 
enzymes after exposure to CNP, which again confirm the more susceptibility in the chronic 
bronchitis-like model than in the normal model. This is possibly reflecting the situation in 
vivo, where it is considered that COPD patients are more sensitivities to particulate matter in 
air pollutions than healthy subjects[203]. Also it has been shown that exposure to 
environmental stressors like ultrafine particles or nanoparticles can accelerate the progression 
of various chronic respiratory diseases like COPD in individuals with impaired lung 
function[204-206]. In line with our results, it has been shown that models built with PBEC 
from severely asthmatic donor produce more CXCL-8 after exposure to PM compared to 
models with cells from healthy donors[207]. Consistently, Kodavanti et al[208] reported that 
bronchitis rat models (SO2 induced) exhibited increased pulmonary injury upon concentrated 
ambient particles exposure than the normal healthy rats. Therefore, our findings of these 
physiologically relevant in vitro models (normal and chronic bronchitis-like model), which 
are comparable with healthy versus pre-disposed individuals are consistent with results from 
in vivo studies that individuals with chronic bronchitis are more susceptible to exposure to 
particles present in air pollution.  
Human bronchial epithelium together with airway macrophages serves as the first line of 
defense. The cooperation and communication between them play a critical role in facility 
reactions of the particles that enter into respiratory system. 
In Paper IV, when co-cultured PBEC-ALI model with THP-1 derived macrophages (PBEC-
ALI/MQ), the inflammatory response (CXCL8, TNFα and NFKB mRNA expression, TIMP-1 
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secretion), oxidative stress effects (HMOX1 mRNA expression) were reduced compared with 
PBEC-ALI. In contrast, some studies reported in submerged culture conditions, when co-
culturing primary epithelial cells or cell lines and macrophages, an amplification of the 
inflammatory response following exposure to ambient particulate matters or DEP was 
observed[209-211]. This deficiency may be due to the variance in cell types, culture conditions 
as well as exposure methods. When adding particles in medium as is the case when culturing 
under submerged condition, might lead to an agglomeration of particles. By using XposeALI 
exposure system which suspend the DEP into aerosolized form allowing a direct cell-particle 
interaction[212, 213]. The direct interaction may further induce phagocytosis of particles by 
MQ and initiate a protective role of MQ after DEP exposure. 
Upon stimulation, macrophages can polarize into different states. Till now, two major 
macrophage phenotypes have been described, the classically activated type1 (M1) 
macrophages and the alternatively activated type 2 (M2) macrophages. Usually, M1-MQ have 
a pro-inflammatory role[214] while M2-MQ exert anti-inflammatory effects[33]. Hence, we 
speculated that the attenuated inflammatory/ oxidative stress markers expressions after DEP 
exposure in PBEC-ALI/MQ compared to PEBC-ALI mentioned above, could be explained by 
an induced polarization of macrophages to M2 phenotype with induced anti-inflammatory 
effects. This hypothesis was confirmed by the detection of typical M2 genes expression with 
anti- inflammatory properties. We found that DEP exposure upregulated the expression of M2-
MQ genes (IL4, MRC1, MCR2 and RETNL) in PBEC-ALI/MQ while there was no such 
increasing in PBEC-ALI or MQ mono-culture, and even a reduced expression of IL13 and 
RETNLA in PBEC-ALI. Besides, an induction of M2-MQ genes like IL10, IL4, IL13 and 
RETNL was found in PBEC-ALI/MQ compared to PBEC-ALI after DEP exposure. However, 
in sham exposure, there was no change in M2-MQ genes expression in PBEC-ALI and PBEC-
ALI/MQ were observed. Therefore, in consistence with other studies[181, 215], we assumed 
that cross-talk between PBEC and MQ together with DEP exposure led to M2-MQ polarization 
as well as anti-inflammatory effects in our multi-cellular models.  
5.4 MODULATION OF TLR PATHWAY 
We have previously shown a decreased TLR2 expression on blood monocytes from farmers 
compared to healthy controls[216]. It has also been demonstrated that smokers have a reduced 
expression of TLR2 in alveolar macrophages[217]. These lower TLR expressions might 
explain the observed increased prevalence of bacterial colonization in the respiratory tract of 
both smokers and farmers[216, 217]. In Paper I, we found that budesonide itself or budesonide 
co-stimulated with PGN/ LPS increased TLR2 mRNA expression in AMQ from smokers with 
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and without COPD. This finding was in line with our previous study performed on PBEC 
cultured submerged, that Bud combined with a TLR ligand or TNF-α synergistically enhanced 
PBEC TLR2 expression[52]. Glucocorticosteroids induce MKP-1 expression leading to 
inhibition of P38 MAPK phosphorylation and the decreased P38 activation could positively 
regulate TLR2 expression[218]. In addition, glucocorticosteroids increase TLR2 expression in 
human airway epithelial cells after incubation with Haemophilus influenza[218]. Furthermore, 
dexamethasone has been shown to increase TLR2 expression in AMQ from COPD 
patients[219]. Therefore, we assume that the glucocorticosteroid may enhance TLR2 
expression to further strengthen immune defense pathways. Augmented TLR expression will 
most likely increase the possibility of PAMPs to bind to these receptors which can provide a 
positive feedback loop to the pro-inflammatory cytokine and chemokines secretion. This 
upregulation of TLR2 expression induced by budesonide appears as a paradox considering its 
anti-inflammatory effects (inhibit PGN/ LPS induced CXCL-8 and TNF-α release). Similar 
findings have been observed in dendritic cells, where glucocorticosteroids increased TLR2/ 
TLR4 expression while decreased the production of pro-inflammatory cytokines as a response 
to stimulation with a TLR agonists[220]. Glucocorticosteroid exerts its anti-inflammatory 
functions by blocking downstream of TLR2 signaling, such as inhibiting the activation of 
related transcription factor (NF-κB or AP-1). However just increasing the TLR2 expression in 
the upstream cannot relieve the inhibitory effects in the downstream effects caused by 
glucocorticosteroid[221]. Therefore, budesonide could have a dualistic effect by both 
increasing the host defense and reducing the inflammatory reaction. We demonstrated that in 
all three groups, TLR4 expression was significantly decreased when AMQ were treated with 
LPS alone. The same inhibitory effects of LPS on TLR4 mRNA expression were showed in 
AMQ from nonsmokers and smokers[222] and in a mouse macrophage cell line [223]. 
However, LPS was found to increase TLR4 gene expression in human neutrophils and 
monocytes[224].  
As both bronchial epithelial cells and macrophage are equipped with TLR, also bronchial 
epithelial cells can modulate the inflammatory response of macrophage through TLR 
signaling[55]. Therefore, we investigate the effects of TLR expression when co-culturing 
PBEC and MQ after DEP exposure.  
In Paper IV, we showed both mRNA and cell surface expression of TLR2 and TLR4 in PBEC 
and MQ from multicellular models after exposure to DEP. The DEP exposure increased both 
TLR2 and TLR4 mRNA expression in PBEC-ALI model, while there was no such alternation 
with the presence of MQ (PBEC-ALI/MQ). The binding of DEP to TLR2/ TLR4 might activate 
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MyD88 or TRIF dependent pathways which increases the transcription potential of 
inflammatory genes[225]. Then the increased TLR expressions in PBEC-ALI upon DEP 
exposure, were in consisted with inflammatory biomarker findings mentioned in section 5.3 
that after DEP exposure, CXCL-8 secretion/mRNA expression and TNFα mRNA expression 
were increased in PBEC-ALI but not in PBEC-ALI/MQ.  
To detect cell surface TLR expression in different cell types, CD68 antibody was used to 
distinguish between PBEC and MQ in the PBEC–ALI/MQ model. Then it was possible to 
detect TLR2/ TLR4 surface expression on PBEC or MQ separately by FACS analysis. In Paper 
IV, we found that the surface expression of TLR2 was increased while TLR4 was decreased 
on both PBEC and MQ in PBEC–ALI/MQ model after DEP exposure. However, such 
alteration could not be found in PBEC-ALI or MQ mono-culture (except TLR4 in PBEC-ALI). 
Interestingly, similar pattern has been shown in Paper I, that the combination of Bud and TLR 
ligands increased TLR2 expression in AMQ, while TLR ligands alone decreased TLR4 
expression. Besides, another study reported that alveolar macrophages, exposed to PM 
contaminated by low or high levels of endotoxin, activated TLR2/4 dependent pathways 
differently. For instance, low levels of endotoxin contamination induced TLR2 transcript 
expression which attenuated TLR4 pathways[226]. Conversely, in epithelial cells, PM did not 
change the TLR2 expression while it augmented TLR4 expression[227]. In dendritic cells, both 
TLR2 and TLR4 expression were downregulated by PM exposure[228]. Therefore, our results 
indicated that the interaction between different cell types could alter TLR expression.  
Worth mentioning is that macrophage surface TLR expression is highly relevant to the 
macrophage polarization process. For instance, M1-MQ contains higher ratio of TLR4 and 
TLR2 surface expression than M2-MQ, also TLR4 deficiency can drive macrophage to skew 
to M2 phenotype[229, 230]. Consistently, in our study after DEP exposure, expression of 
macrophage surface TLR4 was attenuated in PBEC-ALI/MQ, which might strength the finding 
that when exposing our multi-cellular model including both PBEC and MQ to DEP an 
increased M2-MQ polarization was observed. 
Furthermore, the FACS data regarding TLR2/4 surface expression was different from PCR 
data regarding TLR2/4 mRNA expression. This difference might due to that, in PBEC-
ALI/MQ, the surface expression of TLR can be detected on PBEC or MQ separately by FACS, 
but for mRNA expression which detected by RT-PCR, PBEC and MQ cannot be analyzed 
separately. Moreover, FACS analysis detects TLR expression on protein level while RT-PCR 
detects TLR expression on mRNA level, which could also explain the differences.  
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6 CONCLUSIONS 
Paper I: 
 In alveolar macrophage (AMQ) from healthy controls and smokers with and without 
chronic obstructive pulmonary disease (COPD), Toll-like receptor (TLR)  ligands 
increased secretion of pro-inflammatory cytokines and chemokines which was 
attenuated by a glucocorticosteroid.  
 In AMQ from smokers with and without COPD, glucocorticosteroids alone or 
combined with TLR ligands upregulated the TLR2 mRNA expression.  
Paper II:  
 We successfully developed both normal and chronic bronchitis-like human bronchial 
epithelial 3D models by co-culturing primary bronchial epithelial cell (PBEC) with 
fibroblast cell line at air-liquid interface. These 3D models were combind with an 
unique aerosol exposures system--XposeALI.  
 Both normal and chronic bronchitis-like 3D models differentiated into various cell 
types similar to what is found  in vivo and chronic bronchitis-like 3D-model contained 
more mucus producing cells. Therefore, these models can be used to mimic in vivo 
conditions. 
 3D model displayed inflammatory responses to palladium exposure.  
 The 3D model forms part of an in vitro testing strategy to study the cell biology, 
respiratory diseases, and toxicity of inhaled substances withoutrequirement of animal 
studies. 
Paper III: 
 Carbon nanoparticle (CNP) exposure induced inflammatory and oxidative stress 
response in both normal (PBEC-ALI) and chronic bronchitis-like (PBEC-ALI/CB) 
models.  
 Exposure to CNP in the normal model induced both tissue injury and repair markers 
while in bronchitis-like model only the tissue injury marker increased. 
 There was an earlier onset with a significantly stronger reaction in the chronic 
bronchitis-like model compared with normal model.  
 We provide further evidence for individuals with chronic bronchitis are more 
susceptible to exposure to particles present in air pollution.  
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Paper IV: 
 Diesel exhaust particle (DEP) exposure increased the inflammatory and oxidative stress 
responses in PBEC-ALI model, and this induction was reduced by co-culturing with 
MQ.  
 The DEP exposure increased TLR2 but decreased TLR4 surface expressions in both 
PBEC and MQ from PBEC-ALI/MQ.  
 The co-culture of PBEC-ALI and MQ in response to DEP exposure drove the 
polarization of MQ to M2 phenotype, and result in efficient resolution of the 
inflammatory response.  
 Co-cultured models enable cell-cell interationsand is therefore considered to be more 
effective than mono-cell culture in investigating the detailed molecular responses to 
particle exposure. 
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7 FUTURE PERSPECTIVES  
In this thesis, we have established good and reliable human bronchial airway wall models 
which can be used as a realistic and efficient alternative for pulmonary toxicity testing and 
cell-cell interaction studies. Different parts of the lung may respond differently due to 
differences in tissue architecture structure, secretion of mucus and presence of surfactant. 
Therefore, in the future studies, we also want to build alveolar mucosa models. 
The alveolar mucosa consists of alveolar type I and type II cells. Alveolar type I (ATI) cell 
which covering around 90% of the alveolar surface are usually flat and large in size. Alveolar 
type II (ATII) cell which display approximately 10% of the alveolar surface are usually 
cuboidal and smaller in size. The ATI cell plays important roles in gas exchange and ion/protein 
transport. The ATII cell secrets surfactant to serve as a production and also act as progenitor 
cells for the regeneration of ATI cell. As a response to host defense, ATII cell is involved in 
modulating the balance of coagulation and fibrinolysis. On one hand, ATII cell can guide 
neutrophils transmigrate into the alveolar space, on the other hand it can by itself act as effector 
cells by directly or indirectly cross-talk with resident and mobile cells.  
To our knowledge there are no existing commercial ATII cell models available at present, 
and most of the alveolar mucosa models described in the literature are involving tumour or 
immobilized cell lines which might lack biological relevance, due to their genetic alterations 
and lacking essential physiological functions like tight junctions. Therefore, it is necessary 
to develop alveolar mucosa model with primary ATII cell. 
All studies included in this thesis included exposure to one substance at one occasion thus 
reflecting an acute exposure scenario. However, repeated exposure would cause the chronic 
cycle of injury and repair, and significantly change the structure, gene expression and 
function of epithelial cells. Also in Paper IV, we observed the polarization of M2 macrophage 
upon diesel exhaust particle (DEP) exposure which could be speculated to be a normal 
defense response after acute exposure to DEP. However, the effect of chronic exposure which 
might induce an alteration regarding macrophage polarization as a response to a persistent 
inflammation is still unknown. Therefore, a more chronic exposure models would be of 
interest in order to detect chronic effects of different substance by repeated exposure over 
periods of time and also test to expose the models for a combination of particles and/or gases.  
We think that our different models are suited to study disease mechanisms in detail. Therefore, 
we also would like to explore mechanisms of COPD and chronic bronchitis and the 
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mechanisms of action of established and/ or newly developed treatment strategies in our multi-
cellular bronchial mucosa models. 
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